NZ621592B2 - Methods for tagging dna-encoded libraries - Google Patents
Methods for tagging dna-encoded libraries Download PDFInfo
- Publication number
- NZ621592B2 NZ621592B2 NZ621592A NZ62159212A NZ621592B2 NZ 621592 B2 NZ621592 B2 NZ 621592B2 NZ 621592 A NZ621592 A NZ 621592A NZ 62159212 A NZ62159212 A NZ 62159212A NZ 621592 B2 NZ621592 B2 NZ 621592B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- headpiece
- nucleotides
- tag
- building block
- ligation
- Prior art date
Links
- 125000003729 nucleotide group Chemical class 0.000 claims abstract description 422
- 239000002773 nucleotide Substances 0.000 claims abstract description 414
- 238000009739 binding Methods 0.000 claims abstract description 101
- 125000000524 functional group Chemical group 0.000 claims abstract description 45
- 150000003384 small molecules Chemical class 0.000 claims abstract description 31
- 230000001588 bifunctional Effects 0.000 claims abstract description 23
- 239000000126 substance Substances 0.000 claims description 167
- 230000027455 binding Effects 0.000 claims description 92
- 101700085547 ICP0 Proteins 0.000 claims description 53
- 101710006422 PNK/PNL Proteins 0.000 claims description 53
- 229920001223 polyethylene glycol Polymers 0.000 claims description 39
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 101710030587 ligN Proteins 0.000 claims description 15
- 101700077585 ligd Proteins 0.000 claims description 15
- 150000001768 cations Chemical class 0.000 claims description 12
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 6
- UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 claims description 4
- 229960003786 inosine Drugs 0.000 claims description 4
- 229940104230 Thymidine Drugs 0.000 claims description 3
- UUDVSZSQPFXQQM-GIWSHQQXSA-N (2R,3S,4R,5R)-2-(6-aminopurin-9-yl)-3-fluoro-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F UUDVSZSQPFXQQM-GIWSHQQXSA-N 0.000 claims description 2
- GBBJCSTXCAQSSJ-JXOAFFINSA-N 1-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](F)[C@H](O)[C@@H](CO)O1 GBBJCSTXCAQSSJ-JXOAFFINSA-N 0.000 claims description 2
- RFCQJGFZUQFYRF-ZOQUXTDFSA-N 2'-O-methylcytidine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-ZOQUXTDFSA-N 0.000 claims description 2
- HPHXOIULGYVAKW-IOSLPCCCSA-N 2'-O-methylinosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HPHXOIULGYVAKW-IOSLPCCCSA-N 0.000 claims description 2
- FPUGCISOLXNPPC-IOSLPCCCSA-N cordysinin B Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-IOSLPCCCSA-N 0.000 claims description 2
- 229920000272 Oligonucleotide Polymers 0.000 description 218
- 238000006243 chemical reaction Methods 0.000 description 155
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 90
- 239000000047 product Substances 0.000 description 81
- 125000005647 linker group Chemical group 0.000 description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 239000000370 acceptor Substances 0.000 description 43
- 230000015572 biosynthetic process Effects 0.000 description 32
- 238000000034 method Methods 0.000 description 31
- 239000002585 base Substances 0.000 description 30
- 230000002255 enzymatic Effects 0.000 description 30
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 29
- 230000002194 synthesizing Effects 0.000 description 29
- 230000001419 dependent Effects 0.000 description 28
- 238000007792 addition Methods 0.000 description 27
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 25
- 102000003960 Ligases Human genes 0.000 description 24
- 108090000364 Ligases Proteins 0.000 description 24
- 230000003321 amplification Effects 0.000 description 24
- 238000003199 nucleic acid amplification method Methods 0.000 description 24
- 238000006116 polymerization reaction Methods 0.000 description 24
- 125000006239 protecting group Chemical group 0.000 description 24
- 238000010839 reverse transcription Methods 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 19
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- -1 phosphoryl group Chemical group 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 102000004594 DNA Polymerase I Human genes 0.000 description 15
- 108010017826 DNA Polymerase I Proteins 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 15
- 230000002829 reduced Effects 0.000 description 15
- 230000000295 complement Effects 0.000 description 14
- 229940014598 TAC Drugs 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000006011 modification reaction Methods 0.000 description 12
- 238000006366 phosphorylation reaction Methods 0.000 description 12
- 230000000865 phosphorylative Effects 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 150000001345 alkine derivatives Chemical class 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 11
- 239000003960 organic solvent Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 10
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 10
- 150000004713 phosphodiesters Chemical class 0.000 description 10
- 238000001542 size-exclusion chromatography Methods 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 239000011324 bead Substances 0.000 description 9
- 125000002346 iodo group Chemical group I* 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000004429 atoms Chemical group 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 8
- 230000002209 hydrophobic Effects 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 239000011630 iodine Substances 0.000 description 8
- 125000004426 substituted alkynyl group Chemical group 0.000 description 8
- VKYKSIONXSXAKP-UHFFFAOYSA-N Hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 7
- 229960004011 Methenamine Drugs 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 239000004312 hexamethylene tetramine Substances 0.000 description 7
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 125000003396 thiol group Chemical class [H]S* 0.000 description 7
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229940068917 Polyethylene Glycols Drugs 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 230000003247 decreasing Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000007086 side reaction Methods 0.000 description 6
- BSUNTQCMCCQSQH-UHFFFAOYSA-N triazine Chemical compound C1=CN=NN=C1.C1=CN=NN=C1 BSUNTQCMCCQSQH-UHFFFAOYSA-N 0.000 description 6
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 6
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 5
- 229940045145 Uridine Drugs 0.000 description 5
- 230000001594 aberrant Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 5
- 229910052803 cobalt Inorganic materials 0.000 description 5
- 239000010941 cobalt Substances 0.000 description 5
- 238000000326 densiometry Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000000269 nucleophilic Effects 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 102000008422 EC 2.7.1.78 Human genes 0.000 description 4
- 108010021757 EC 2.7.1.78 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000010222 PCR analysis Methods 0.000 description 4
- 102000030951 Phosphotransferases Human genes 0.000 description 4
- 108091000081 Phosphotransferases Proteins 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 230000036462 Unbound Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 239000012038 nucleophile Substances 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 238000002515 oligonucleotide synthesis Methods 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 230000001603 reducing Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 150000003852 triazoles Chemical group 0.000 description 4
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 3
- LZKGFGLOQNSMBS-UHFFFAOYSA-N 4,5,6-trichlorotriazine Chemical compound ClC1=NN=NC(Cl)=C1Cl LZKGFGLOQNSMBS-UHFFFAOYSA-N 0.000 description 3
- 101700078037 BIND Proteins 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 102000016928 DNA-Directed DNA Polymerase Human genes 0.000 description 3
- 108010014303 DNA-Directed DNA Polymerase Proteins 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 235000017168 chlorine Nutrition 0.000 description 3
- VMQMZMRVKUZKQL-UHFFFAOYSA-N cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
- 238000006352 cycloaddition reaction Methods 0.000 description 3
- 150000001993 dienes Chemical class 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical class C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 235000011147 magnesium chloride Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 230000001590 oxidative Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- IEKWPPTXWFKANS-UHFFFAOYSA-K trichlorocobalt Chemical compound Cl[Co](Cl)Cl IEKWPPTXWFKANS-UHFFFAOYSA-K 0.000 description 3
- MGNZXYYWBUKAII-UHFFFAOYSA-N 1,3-Cyclohexadiene Chemical class C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- BSXPDVKSFWQFRT-UHFFFAOYSA-N 1-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CC=C2N(O)N=NC2=N1 BSXPDVKSFWQFRT-UHFFFAOYSA-N 0.000 description 2
- NOKYWNGQHBWZAP-UHFFFAOYSA-N 1-methoxybuta-1,3-dienoxy(trimethyl)silane Chemical class C[Si](C)(C)OC(OC)=CC=C NOKYWNGQHBWZAP-UHFFFAOYSA-N 0.000 description 2
- WUIJTQZXUURFQU-UHFFFAOYSA-N 1-methylsulfonylethene Chemical compound CS(=O)(=O)C=C WUIJTQZXUURFQU-UHFFFAOYSA-N 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 2,6-Diaminopurine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- GVPFVAHMJGGAJG-UHFFFAOYSA-L Cobalt(II) chloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L Copper(II) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N Cyclopentadiene Chemical class C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 238000005698 Diels-Alder reaction Methods 0.000 description 2
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 2
- 102000033147 ERVK-25 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000009617 Inorganic Pyrophosphatase Human genes 0.000 description 2
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L MANGANESE CHLORIDE Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N N,N'-Diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N Psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 229920001914 Ribonucleotide Polymers 0.000 description 2
- 229960005055 SODIUM ASCORBATE Drugs 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000010462 azide-alkyne Huisgen cycloaddition reaction Methods 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-O aziridinium Chemical class C1C[NH2+]1 NOWKCMXCCJGMRR-UHFFFAOYSA-O 0.000 description 2
- DMLAVOWQYNRWNQ-UHFFFAOYSA-N azobenzene Chemical compound C1=CC=CC=C1N=NC1=CC=CC=C1 DMLAVOWQYNRWNQ-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N butadiene Chemical class C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000005591 charge neutralization Effects 0.000 description 2
- 125000001309 chloro group Chemical class Cl* 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 229940000406 drug candidates Drugs 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002427 irreversible Effects 0.000 description 2
- 238000007169 ligase reaction Methods 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000004038 photonic crystal Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000023 polynucleotide Polymers 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 108091007521 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 238000005987 sulfurization reaction Methods 0.000 description 2
- PWBHRVGYSMBMIO-UHFFFAOYSA-M tributylstannanylium;acetate Chemical compound CCCC[Sn](CCCC)(CCCC)OC(C)=O PWBHRVGYSMBMIO-UHFFFAOYSA-M 0.000 description 2
- TYJPSIQEEXOQLC-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate Chemical compound CC(C)(C)OC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O TYJPSIQEEXOQLC-UHFFFAOYSA-N 0.000 description 1
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-Triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- WKGZJBVXZWCZQC-UHFFFAOYSA-N 1-(1-benzyltriazol-4-yl)-N,N-bis[(1-benzyltriazol-4-yl)methyl]methanamine Chemical compound C=1N(CC=2C=CC=CC=2)N=NC=1CN(CC=1N=NN(CC=2C=CC=CC=2)C=1)CC(N=N1)=CN1CC1=CC=CC=C1 WKGZJBVXZWCZQC-UHFFFAOYSA-N 0.000 description 1
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 1
- HZOYZGXLSVYLNF-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;1H-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.O=C1NC(N)=NC2=C1NC=N2 HZOYZGXLSVYLNF-UHFFFAOYSA-N 0.000 description 1
- NOIRDLRUNWIUMX-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;6-amino-1H-pyrimidin-2-one Chemical compound NC=1C=CNC(=O)N=1.O=C1NC(N)=NC2=C1NC=N2 NOIRDLRUNWIUMX-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- GEYUSEZSTCVKLX-UHFFFAOYSA-N 2-phenyl-N,N-bis[2-phenyl-1-(2H-triazol-4-yl)ethyl]-1-(2H-triazol-4-yl)ethanamine Chemical compound C=1C=CC=CC=1CC(C=1N=NNC=1)N(C(CC=1C=CC=CC=1)C=1N=NNC=1)C(C=1N=NNC=1)CC1=CC=CC=C1 GEYUSEZSTCVKLX-UHFFFAOYSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-UHFFFAOYSA-N 3,4,5-trihydroxypentanal Chemical class OCC(O)C(O)CC=O ASJSAQIRZKANQN-UHFFFAOYSA-N 0.000 description 1
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 1
- AVVLVCYNVBXDSH-UHFFFAOYSA-N 4-[(4,6-dimethoxy-1,3,5-triazin-2-yl)methyl]morpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC(C[NH+]2CCOCC2)=N1 AVVLVCYNVBXDSH-UHFFFAOYSA-N 0.000 description 1
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
- SSMVDPYHLFEAJE-UHFFFAOYSA-N 4-azidoaniline Chemical compound NC1=CC=C(N=[N+]=[N-])C=C1 SSMVDPYHLFEAJE-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-Bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-Methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- SBZDIRMBQJDCLB-UHFFFAOYSA-N 5-azidopentanoic acid Chemical compound OC(=O)CCCCN=[N+]=[N-] SBZDIRMBQJDCLB-UHFFFAOYSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-Methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N Adenosine monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 Adenosine phosphate Drugs 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M Copper(I) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-XVFCMESISA-N Cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N Deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-protein coupled receptors Human genes 0.000 description 1
- 108090000045 G-protein coupled receptors Proteins 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- NYHBQMYGNKIUIF-PXMDKTAGSA-N Guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1O[C@@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-PXMDKTAGSA-N 0.000 description 1
- 229940029575 Guanosine Drugs 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N Isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 102100008691 MBD2 Human genes 0.000 description 1
- 101700064880 MBD2 Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- IMXSWQZTDZXUSD-UHFFFAOYSA-N N#CCCP([O-])([O-])(N(C(C)C)C(C)C)CCCCCCNC(=O)C(F)(F)F Chemical compound N#CCCP([O-])([O-])(N(C(C)C)C(C)C)CCCCCCNC(=O)C(F)(F)F IMXSWQZTDZXUSD-UHFFFAOYSA-N 0.000 description 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 102000030002 Prion Proteins Human genes 0.000 description 1
- 108091000054 Prion Proteins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N Pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 238000004617 QSAR study Methods 0.000 description 1
- 108060006943 RdRp Proteins 0.000 description 1
- 229920000970 Repeated sequence (DNA) Polymers 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 101710014726 SS3 Proteins 0.000 description 1
- 101700068286 SUS2 Proteins 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N Tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HWTCRCIIHHJATF-UHFFFAOYSA-L [O-]P([O-])(I)=S Chemical compound [O-]P([O-])(I)=S HWTCRCIIHHJATF-UHFFFAOYSA-L 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000000089 arabinosyl group Chemical class C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N dCyd Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000003100 immobilizing Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 238000002898 library design Methods 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 102000016397 methyltransferase family Human genes 0.000 description 1
- 108060004795 methyltransferase family Proteins 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N mn2+ Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 125000004437 phosphorous atoms Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 150000004291 polyenes Polymers 0.000 description 1
- 230000000379 polymerizing Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- HRLUZSSGBKDEGK-QMMMGPOBSA-N tert-butyl (2S)-2-(azidomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CN=[N+]=[N-] HRLUZSSGBKDEGK-QMMMGPOBSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 239000000700 tracer Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
- C40B50/16—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support involving encoding steps
Abstract
method of tagging a first library comprising an oligonucleotide-encoded small molecule or peptide is disclosed. A headpiece having a first functional group and a second functional group is provided in step (i). The headpiece comprises at least one 2’-substituted nucleotide and the headpiece comprises a 2’-substituted nucleotide at the 5’-terminus and/or 3’-terminus. In step (ii) the first functional group of the headpiece is bound to a first component of the small molecule or peptide. The headpiece is directly connected to the first component or the headpiece is indirectly connected to the first component by a bifunctional linker; and in step (iii) the second functional group of the headpiece is bound to a first building block tag to form a complex. The steps (ii) and (iii) can be performed in any order and the first building block tag encodes for the binding reaction of the step (ii), thereby providing a tagged library. A complex comprises a headpiece and a building block tag. The tag comprises from 5 to 20 nucleotides, a 2’-substituted nucleotide at the 5’-terminus, and a 2’- substituted nucleotide at the 3’-terminus and the headpiece is directly connected to a small molecule or peptide or the headpiece is indirectly connected to a small molecule or peptide by a bifunctional linker. ises a 2’-substituted nucleotide at the 5’-terminus and/or 3’-terminus. In step (ii) the first functional group of the headpiece is bound to a first component of the small molecule or peptide. The headpiece is directly connected to the first component or the headpiece is indirectly connected to the first component by a bifunctional linker; and in step (iii) the second functional group of the headpiece is bound to a first building block tag to form a complex. The steps (ii) and (iii) can be performed in any order and the first building block tag encodes for the binding reaction of the step (ii), thereby providing a tagged library. A complex comprises a headpiece and a building block tag. The tag comprises from 5 to 20 nucleotides, a 2’-substituted nucleotide at the 5’-terminus, and a 2’- substituted nucleotide at the 3’-terminus and the headpiece is directly connected to a small molecule or peptide or the headpiece is indirectly connected to a small molecule or peptide by a bifunctional linker.
Description
METHODS FOR TAGGING DNA-ENCODED LIBRARIES
Cross-reference to Related Applications
This application claims benefit of U.S. Provisional Application Nos. 61/531,820, filed September
7, 2011, and 61/536,929, filed September 20, 2011, each of which is hereby incorporated by reference.
Background of the Invention
In general, this invention relates to DNA-encoded libraries of compounds and methods of using
and creating such libraries. The invention also relates generally to compositions for use in such libraries.
DNA-encoded combinatorial libraries afford many benefits for drug discovery. These libraries
can provide a large number of diverse compounds that can be rapidly screened and interrogated. To
further increase complexity, various steps of the discovery process can be programmed and automated.
These steps include the use of multi-step, split-and-pool synthesis to add building blocks to atomic or
polyatomic scaffolds and the use of enzymatic and/or chemical ligation to add DNA tags that encode both
the synthetic steps and the building blocks.
Despite these benefits, numerous issues can arise when very large or complex libraries must be
synthesized and deconvoluted. As the size of the library increases, improved methods may be needed to
provide high yields of tag ligation. To create libraries under diverse reaction conditions, stable ligated
nucleotide constructs would be beneficial, such as constructs that are stable under conditions of high pH
and elevated temperature. To simplify deconvolution of tags, the sequence of the tags could be
recognized by DNA- or RNA-dependent polymerases, such that tag population demographics can be
determined by template-dependent polymerization and sequence determination. Difficulties may arise
when creating a library having all of these beneficial attributes. Accordingly, there exists a need for
improved, more robust methods of screening and identifying small compounds in DNA-encoded libraries.
Summary of the Invention
The present invention features methods of creating libraries, where the method includes one or
more conditions that improve single-stranded ligation of tags, and compositions for use in creating
libraries. Exemplary conditions include the use of one or more 2’-substituted bases within the tags, such
as 2’-O-methyl or 2’-fluoro; the use of tags of particular length; the use of one or more enzymes;
optionally, the inclusion of error-recognition capabilities in the tag design; and/or the use of one or more
agents during ligation.
Accordingly, in one aspect the present invention relates to a method of tagging a first library
comprising an oligonucleotide-encoded small molecule or peptide, said method comprising:
(i) providing a headpiece having a first functional group and a second functional group, wherein said
headpiece comprises at least one 2’-substituted nucleotide, wherein said headpiece comprises a
2’-substituted nucleotide at the 5’-terminus and/or 3’-terminus;
(ii) binding said first functional group of said headpiece to a first component of said small molecule
or peptide, wherein said headpiece is directly connected to said first component or said headpiece
is indirectly connected to said first component by a bifunctional linker; and
(iii) binding said second functional group of said headpiece to a first building block tag to form a
complex,
wherein said steps (ii) and (iii) can be performed in any order and wherein said first building block tag
encodes for the binding reaction of said step (ii), thereby providing a tagged library.
In another aspect the present invention relates to a complex comprising a headpiece and a
building block tag, wherein said tag comprises from 5 to 20 nucleotides, a 2’-substituted nucleotide at the
5’-terminus, and a 2’-substituted nucleotide at the 3’-terminus, wherein said headpiece is directly
connected to a small molecule or peptide or said headpiece is indirectly connected to a small molecule or
peptide by a bifunctional linker.
Certain statements that appear below are broader than what appears in the statements of the
invention above. These statements are provided in the interests of providing the reader with a better
understanding of the invention and its practice. The reader is directed to the accompanying claim set
which defines the scope of the invention.
Also described herein is a method of tagging a first library including an oligonucleotide-encoded
chemical entity, the method including: (i) providing a headpiece having a first functional group and a
second functional group, where the headpiece includes at least one 2’-substituted nucleotide; (ii) binding
the first functional group of the headpiece to a first component of the chemical entity, where the
headpiece is directly connected to the first component or the headpiece is indirectly connected to the first
component by a bifunctional linker (e.g., a poly ethylene glycol linker or –(CH CH O) CH CH -, where n
2 2 n 2 2
is an integer from 1 to 50); and (iii) binding the second functional group of the headpiece to a first
building block tag to form a complex, where steps (ii) and (iii) can be performed in any order and where
the first building block tag encodes for the binding reaction of step (ii), thereby providing a tagged
library.
In some embodiments, the headpiece includes a 2’-substituted nucleotide at one or more of the
’-terminus, the 3’-terminus, or the internal position of the headpiece. In particular embodiments, the
headpiece includes the 2’-substituted nucleotide and the second functional group at the 5’-terminus or at
the 3’-terminus.
In other embodiments, the first building block tag includes at least one (e.g., at least two, three,
four, five, or more) 2’-substituted nucleotides. In particular embodiments, the first building block tag
includes a 2’-substituted nucleotide at one or more of the 5’-terminus, the 3’-terminus, or the internal
position of the first building block tag (e.g., a 2’-O-methyl nucleotide or a 2’-fluoro nucleotide at both of
the 5’- and 3’-termini). In some embodiments, the first building block tag includes a protecting group at
the 3’-terminus or at the 5’-terminus.
In any of the embodiments described herein, the 2’-substituted nucleotide is a 2’-O-methyl
nucleotide (e.g., 2’-O-methyl guanine or 2’-O-methyl uracil) or a 2’-fluoro nucleotide (e.g., 2’-fluoro
guanine, or 2’-fluoro uracil).
In any of the above embodiments, step (ii) may include joining, binding, or operatively
associating the headpiece directly to the first component (e.g., a scaffold or a first building block). In yet
other embodiments, step (ii) includes binding the headpiece indirectly to the first component (e.g., a
scaffold or a first building block) via a bifunctional linker (e.g., the method includes binding the
headpiece with the first functional group of the linker and binding the first component with the second
functional group of the linker).
In any of the above embodiments, the method may further include (iv) binding a second building
block tag to the 5’-terminus or 3’-terminus of the complex; and (v) binding a second component (e.g., a
first building block or a second building block) of the chemical library to the first component, where steps
(iv) and (v) can be performed in any order. In some embodiments, the second building block tag encodes
for the binding reaction of step (v). In other embodiments, step (iv) may include binding the second
building block tag to the 5’-terminus of the complex; the complex includes a phosphate group at the 5’-
terminus; and the second building block tag includes a hydroxyl group at both of the 3’- and 5’-termini.
In other embodiments, step (iv) may further include purifying the complex and reacting the complex with
a polynucleotide kinase to form a phosphate group on the 5’-terminus prior to binding the second
building block tag. In other embodiments, step (iv) may include binding the second building block tag to
the 3’-terminus of the complex; the complex includes a protecting group at the 3’-terminus; and the
second building block tag includes a phosphate group at the 5’-terminus and a protecting group at the 3’-
terminus. In yet other embodiments, step (iv) may further include reacting the complex with a
hydrolyzing agent to release the protecting group from the complex prior to binding the second building
block tag to the complex.
In further embodiments, the second building block tag includes a 2’-substituted nucleotide (e.g., a
2’-O-methyl nucleotide or a 2’-fluoro nucleotide) at one or more of the 5’-terminus, the 3’-terminus, or
the internal position of the second building block tag (e.g., a 2’-O-methyl nucleotide and/or a 2’-fluoro
nucleotide at both of the 5’- and 3’-termini).
In some embodiments, step (iv) may include the use of an RNA ligase (e.g., T4 RNA ligase)
and/or a DNA ligase (e.g., a ssDNA ligase) to bind the second building block tag to the complex (e.g.,
may include the use of both RNA ligase and the DNA ligase).
In other embodiments, step (iii) may include the use of an RNA ligase (e.g., T4 RNA ligase)
and/or a DNA ligase (e.g., ssDNA ligase) to bind the headpiece to the first building block tag (e.g., may
include the use of both RNA ligase and the DNA ligase).
In further embodiments, step (iii) and/or step (iv), if present, may include the use of poly ethylene
glycol and/or one or more soluble multivalent cations (e.g., magnesium chloride, manganese (II) chloride,
or hexamine cobalt (III) chloride). In some embodiments, the poly ethylene glycol is in an amount from
about 25% (w/v) to about 35% (w/v) (e.g., from about 25% (w/v) to about 30 % (w/v), from about 30 %
(w/v) to about 35% (w/v), or about 30% (w/v)). In other embodiments, the poly ethylene glycol has an
average molecular weight from about 3,000 to about 5,500 Daltons (e.g., about 4,600 Daltons). In other
embodiments, the one or more soluble multivalent cations are in an amount of from about 0.05 mM to
about 10.5 mM (e.g., from 0.05 mM to 0.5 mM, from 0.05 mM to 0.75 mM, from 0.05 mM to 1.0 mM,
from 0.05 mM to 1.5 mM, from 0.05 mM to 2.0 mM, from 0.05 mM to 3.0 mM, from 0.05 mM to 4.0
mM, from 0.05 mM to 5.0 mM, from 0.05 mM to 6.0 mM, from 0.05 mM to 7.0 mM, from 0.05 mM to
8.0 mM, from 0.05 mM to 9.0 mM, from 0.05 mM to 10.0 mM, from 0.1 mM to 0.5 mM, from 0.1 mM
to 0.75 mM, from 0.1 mM to 1.0 mM, from 0.1 mM to 1.5 mM, from 0.1 mM to 2.0 mM, from 0.1 mM
to 3.0 mM, from 0.1 mM to 4.0 mM, from 0.1 mM to 5.0 mM, from 0.1 mM to 6.0 mM, from 0.1 mM to
7.0 mM, from 0.1 mM to 8.0 mM, from 0.1 mM to 9.0 mM, from 0.1 mM to 10.0 mM, from 0.1 mM to
.5 mM, from 0.5 mM to 0.75 mM, from 0.5 mM to 1.0 mM, from 0.5 mM to 1.5 mM, from 0.5 mM to
2.0 mM, from 0.5 mM to 3.0 mM, from 0.5 mM to 4.0 mM, from 0.5 mM to 5.0 mM, from 0.5 mM to
6.0 mM, from 0.5 mM to 7.0 mM, from 0.5 mM to 8.0 mM, from 0.5 mM to 9.0 mM, from 0.5 mM to
.0 mM, from 0.5 mM to 10.5 mM, from 0.75 mM to 1.0 mM, from 0.75 mM to 1.5 mM, from 0.75 mM
to 2.0 mM, from 0.75 mM to 3.0 mM, from 0.75 mM to 4.0 mM, from 0.75 mM to 5.0 mM, from 0.75
mM to 6.0 mM, from 0.75 mM to 7.0 mM, from 0.75 mM to 8.0 mM, from 0.75 mM to 9.0 mM, from
0.75 mM to 10.0 mM, from 0.75 mM to 10.5 mM, from 1.0 mM to 1.5 mM, from 1.0 mM to 2.0 mM,
from 1.0 mM to 3.0 mM, from 1.0 mM to 4.0 mM, from 1.0 mM to 5.0 mM, from 1.0 mM to 6.0 mM,
from 1.0 mM to 7.0 mM, from 1.0 mM to 8.0 mM, from 1.0 mM to 9.0 mM, from 1.0 mM to 10.0 mM,
from 1.0 mM to 10.5 mM, from 1.5 mM to 2.0 mM, from 1.5 mM to 3.0 mM, from 1.5 mM to 4.0 mM,
from 1.5 mM to 5.0 mM, from 1.5 mM to 6.0 mM, from 1.5 mM to 7.0 mM, from 1.5 mM to 8.0 mM,
from 1.5 mM to 9.0 mM, from 1.5 mM to 10.0 mM, from 1.5 mM to 10.5 mM, from 2.0 mM to 3.0 mM,
from 2.0 mM to 4.0 mM, from 2.0 mM to 5.0 mM, from 2.0 mM to 6.0 mM, from 2.0 mM to 7.0 mM,
from 2.0 mM to 8.0 mM, from 2.0 mM to 9.0 mM, from 2.0 mM to 10.0 mM, and from 2.0 mM to 10.5
mM). In some embodiments, one or more multivalent cations are in an amount of about 1 mM (e.g., from
0.5 mM to 1.5 mM). In a particular embodiment, the multivalent cation is in the form of hexamine cobalt
(III) chloride.
In other embodiments, the method further includes separating the complex from any unreacted
tag or unreacted headpiece before any one of binding steps (ii)-(v). In other embodiments, the method
further includes purifying the complex before any one of binding steps (ii)-(v). In other embodiments,
the method further includes binding one or more additional components (e.g., a scaffold or a first building
block) and one or more additional building block tags, in any order and after any one of binding step (ii)-
(v).
Also described herein is a method of tagging a first library including an oligonucleotide-encoded
chemical entity, the method including: (i) providing a headpiece having a first functional group and a
second functional group, where the headpiece includes a 2’-substituted nucleotide at the 5’-terminus,
optionally one or more nucleotides at the internal position of the headpiece, and a protecting group at the
2’-position and/or the 3’-position at the 3’-terminus; (ii) binding the first functional group of the
headpiece to a first component of the chemical entity, where the headpiece is directly connected to the
first component or the headpiece is indirectly connected to the first component by a bifunctional linker;
and (iii) binding the second functional group of the headpiece to a first building block tag, where the first
building block tag includes a 2’-substituted nucleotide and a hydroxyl group at the 5’-terminus, optionally
one or more nucleotides at the internal position of the tag, and a 2’-substituted nucleotide and a hydroxyl
group at the 3’-terminus; where steps (ii) and (iii) can be performed in any order and where the first
building block tag encodes for the binding reaction of step (ii), thereby providing a tagged library.
In some embodiments, the 2’-substituted nucleotide is a 2’-O-methyl nucleotide (e.g., 2’-O-
methyl guanine) or a 2’-fluoro nucleotide (e.g., 2’-fluoro guanine). In other embodiments, one or more
nucleotides at the internal position of the headpiece are 2’-deoxynucleotides. In yet other embodiments,
the bifunctional linker is a poly ethylene glycol linker (e.g., -(CH CH O) CH CH -, where n is an integer
2 2 n 2 2
from 1 to 50).
In other embodiments, one or more nucleotides (e.g., one or more 2’-deoxynucleotides) are
present at the internal position of the headpiece or the tag.
In some embodiments, step (iii) may include the use of one or more soluble multivalent cations
(e.g., magnesium chloride, manganese (II) chloride, or hexamine cobalt (III) chloride), poly ethylene
glycol (e.g., having an average molecular weight of about 4,600 Daltons), and RNA ligase (e.g., T4 RNA
ligase).
Also described herein are methods to identify and/or discover a chemical entity, the method
including tagging a first library including an oligonucleotide-encoded chemical entity (e.g., including
steps (i) to (iii) and optionally including steps (iv) to (v)) and selecting for a particular characteristic or
function (e.g., selecting for binding to a protein target including exposing the oligonucleotide-encoded
chemical entity or chemical entity to the protein target and selecting the one or more oligonucleotide-
encoded chemical entities or chemical entities that bind to the protein target (e.g., by using size exclusion
chromatography)). Also described herein is a complex including a headpiece and a building block tag,
where the tag includes from 5 to 20 nucleotides, a 2’-substituted nucleotide at the 5’-terminus, and a 2’-
substituted nucleotide at the 3’-terminus. In some embodiments, the 2’-substituted nucleotide at the 5’-
terminus and/or 3’-terminus is a 2’-O-methyl nucleotide (e.g., 2’-O-methyl guanine or 2’-O-methyl
uracil) or a 2’-fluoro nucleotide (e.g., 2’-fluoro guanine or 2’-fluoro uracil). In particular embodiments,
the headpiece includes a hairpin structure. In some embodiments, the headpiece includes a 2’-substituted
nucleotide at one or more of the 5’-terminus, the 3’-terminus, or the internal position of the headpiece. In
other embodiments, the headpiece further includes a preadenylated 5’-terminus. In yet other
embodiments, the headpiece includes from 5 to 20 nucleotides.
In any of the above embodiments, the headpiece, the first building block tag, the second building
block tag, or the one or more additional building block tags, if present, includes a preadenylated 5’-
terminus.
In any of the above embodiments, the method further includes binding one or more (e.g., one,
two, three, four, five, six, seven, eight, nine, or ten) additional building block tags to the complex and
binding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) additional components
(e.g., scaffolds or building blocks) to the complex, where the one or more additional building block tag
encodes for the one or more additional components or encodes for the binding reaction of one or more
additional components, thereby providing a tagged library.
In any of the above embodiments, the 2’-substituted nucleotide is a 2’-O-methyl nucleotide, such
as 2’-O-methyl guanine, 2’-O-methyl uracil, 2’-O-methyl adenosine, 2’-O-methyl thymidine, 2’-O-
methyl inosine, 2’-O-methyl cytidine, or 2’-O-methyl diamino purine. Alternatively, in any of the above
embodiments, the 2’-substituted nucleotide is a 2’-fluoro nucleotide, such as 2’-fluoro guanine, 2’-fluoro
uracil, 2’-fluoro adenosine, 2’-fluoro thymidine, 2’-fluoro inosine, 2’-fluoro cytidine, or 2’-fluoro
diamino purine.
In any of the above embodiments, the RNA ligase is T4 RNA ligase and/or the DNA ligase is a
ssDNA ligase.
In any of the above embodiments, the method includes a plurality of headpieces. In some
embodiments of this method, each headpiece of the plurality of headpieces includes an identical sequence
region and a different encoding region. In particular embodiments, the identical sequence region is a
primer binding region. In other embodiments, the different encoding region is an initial building block
tag that encodes for the headpiece or for an addition of an initial component.
In any of the above embodiments, binding in at least one of steps (ii)-(iv), if present, includes
enzyme ligation and/or chemical ligation. In some embodiments, enzymatic ligation includes use of an
RNA ligase (e.g., T4 RNA ligase) or a DNA ligase (e.g., ssDNA ligase). In other embodiments,
enzymatic ligation includes use of an RNA ligase (e.g., T4 RNA ligase) and a DNA ligase (e.g., ssDNA
ligase). In some embodiments, chemical ligation includes use of one or more chemically co-reactive
pairs (e.g., a pair including an optionally substituted alkynyl group with an optionally substituted azido
group; a pair including an optionally substituted diene having a 4 π electron system (e.g., an optionally
substituted 1,3-unsaturated compound, such as optionally substituted 1,3-butadiene, 1-methoxy
trimethylsilyloxy-1,3-butadiene, cyclopentadiene, cyclohexadiene, or furan) with an optionally
substituted dienophile or an optionally substituted heterodienophile having a 2 π electron system (e.g., an
optionally substituted alkenyl group or an optionally substituted alkynyl group); a pair including a
nucleophile (e.g., an optionally substituted amine or an optionally substituted thiol) with a strained
heterocyclyl electrophile (e.g., optionally substituted epoxide, aziridine, aziridinium ion, or episulfonium
ion); a pair including a phosphorothioate group with an iodo group (e.g., a phosphorothioate group at the
3’-terminus and an iodo group at the 5’-terminus); or a pair including an aldehyde group with an amino
group (e.g., a primary amino or a secondary amino group, including a hydrazido group)). In particular
embodiments, the chemically co-reactive pair produces a resultant spacer having a length from about 4 to
about 24 atoms (e.g., from about 4 to about 10 atoms). In other embodiments, chemical ligation includes
use of a phosphorothioate group (e.g., at the 3’-terminus) and an iodo group (e.g., at the 5’-terminus). In
further embodiments, chemical ligation includes a splint oligonucleotide in the binding reaction. In some
embodiments, the chemical ligation includes use of a phosphorothioate group (e.g., at the 3’-terminus of
the headpiece, the first building block tag, the second building block tag, the one or more additional
building block tags, the library-identifying tag, the use tag, and/or the origin tag, if present), an iodo
group (e.g., at the 5’-terminus of the headpiece, the first building block tag, the second building block tag,
the one or more additional building block tags, the library-identifying tag, the use tag, and/or the origin
tag, if present), and a splint oligonucleotide in the binding reaction, where the use avoids use of one or
more protecting groups. In other embodiments, chemical ligation of multiple tags comprises alternating
use of orthogonal chemically co-reactive pairs (e.g., any two or more chemically co-reactive pairs
described herein) for ligating successive tags.
In any of the above embodiments, the headpiece may include a single-stranded (e.g., hairpin)
structure.
In any of the above embodiments, the headpiece, the first building block tag, the second building
block tag, the one or more additional building block tags, the library-identifying tag, the use tag, and/or
the origin tag, if present, includes a sequence that is substantially identical (e.g., at least 50%, 60%, 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to any sequence described herein
(e.g., the sequence in any one of SEQ ID NOs: 6-21, 26, 27, or 29-31), or a sequence that is
complementary to a sequence that is substantially identical (e.g., at least 50%, 60%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to any sequence described herein (e.g., the
sequence in any one of SEQ ID NOs: 6-21, 26, 27, or 29-31). In particular embodiments, the first
building block tag, the second building block tag, the one or more additional building block tags, the
library-identifying tag, the use tag, and/or the origin tag, if present, further includes a sequence that is
substantially identical (e.g., at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%,
or 100% identical) to the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
In any of the above embodiments, the methods or complexes include only single-stranded
molecules, where the headpiece, the first building block tag, the second building block tag, and/or the one
or more additional building block tags are single-stranded. In some embodiments, one or more of the
single-stranded molecules have a hairpin structure. In particular embodiments, the headpiece includes a
hairpin structure and the one or more building block tags do not include a hairpin structure.
In any of the above embodiments, the method further comprises one or more optional steps to
diversify the library or to interrogate the members of the library, as described herein. In some
embodiments, the method further comprises identifying a small drug-like library member that binds or
inactivates a protein of therapeutic interest. In other embodiments, the method further comprises
contacting a member of the library with a biological target under conditions suitable for at least one
member of the library to bind to the target, removing one or more library members that do not bind to the
target, and analyzing the one or more oligonucleotide tags associated with them.
As described herein, the use of single-stranded molecules (e.g., including hairpin molecules)
could have numerous benefits. Accordingly, in any of the embodiments described herein, the methods
and complexes include a headpiece, one or more building block tags, a complex, a chemical entity, a
molecule, or any member of a tagged library having decreased mass, increased solubility (e.g., in an
organic solvent), decreased cost, increased reactivity, increased target accessibility, decreased
hydrodynamic radius, and/or increased accuracy of analytical assessments, as compared to a method
including one or more double-stranded molecules (e.g., a double-stranded headpiece or a double-stranded
building block tag). In some embodiments, each of the building block tags (e.g., the first building block
tag, the second building block tag, and/or one or more additional building block tags, if present) has about
the same mass (e.g., each building block tag has a mass that is about +/- 10% from the average mass
between two or more building block tags). In particular embodiments, the building block tag has a
decreased mass (e.g., less than about 15,000 Daltons, about 14,000 Daltons, about 13,000 Daltons, about
12,000 Daltons, about 11,000 Daltons, about 10,000 Daltons, about 9,000 Daltons, about 8,000 Daltons,
about 7,500 Daltons, about 7,000 Daltons, about 6,000 Daltons, about 6,500 Daltons, about 5,000
Daltons, about 5,500 Daltons, about 4,000 Daltons, about 4,500 Daltons, or about 3,000 Daltons)
compared to a double-stranded tag (e.g., a double-stranded tag having a mass of about 15,000 Daltons,
about 14,000 Daltons, about 13,000 Daltons, or about 12,000 Daltons). In other embodiments, the
building block tag has a reduced length compared to a double-stranded tag (e.g., a double-stranded tag
having a length of less than about 20 nucleotides, less than about 19 nucleotides, less than about 18
nucleotides, less than about 17 nucleotides, less than about 16 nucleotides, less than about 15 nucleotides,
less than about 14 nucleotides, less than about 13 nucleotides, less than about 12 nucleotides, less than
about 11 nucleotides, less than about 10 nucleotides, less than about 9 nucleotides, less than about 8
nucleotides, or less than about 7 nucleotides). In some embodiments, one or more building block tags or
members of the library lack a primer binding region and/or a constant region (e.g., during a selection step,
such as selection using size exclusion chromatography). In some embodiments, one or more building
block tags or members of the library have a reduced constant region (e.g., a length less than about 30
nucleotides, less than about 25 nucleotides, less than about 20 nucleotides, less than about 19 nucleotides,
less than about 18 nucleotides, less than about 17 nucleotides, less than about 16 nucleotides, less than
about 15 nucleotides, less than about 14 nucleotides, less than about 13 nucleotides, less than about 12
nucleotides, less than about 11 nucleotides, less than about 10 nucleotides, less than about 9 nucleotides,
less than about 8 nucleotides, or less than about 7 nucleotides). In other embodiments, the methods
include a headpiece that encodes for a molecule, a portion of a chemical entity, a binding reaction (e.g.,
chemical or enzymatic ligation) of a step, or the identity of a library, where the encoding headpiece
eliminates the need of an additional building block tag to encode such information.
In any of the above embodiments, an oligonucleotide (e.g., the headpiece, the first building block
tag, the second building block tag, and/or one or more additional building block tags, if present) encodes
for the identity of the library. In some embodiments, the oligonucleotide (e.g., the headpiece, the first
building block tag, the second building block tag, and/or one or more additional building block tags, if
present) includes a first library-identifying sequence, where the sequence encodes for the identity of the
first library. In particular embodiments, the oligonucleotide is a first library-identifying tag. In some
embodiments, the method includes providing a first library-identifying tag, where the tag includes a
sequence that encodes for a first library, and/or binding the first library-identifying tag to the complex. In
some embodiments, the method includes providing a second library and combining the first library with a
second library. In further embodiments, the method includes providing a second library-identifying tag,
where the tag includes a sequence that encodes for a second library.
In any of the above embodiments, an oligonucleotide (e.g., a headpiece and/or one or more
building blocks) encodes for the use of the member of the library (e.g., use in a selection step or a binding
step, as described herein). In some embodiments, the oligonucleotide (e.g., the headpiece, the first
building block tag, the second building block tag, and/or one or more additional building block tags, if
present) includes a use sequence, where the sequence encodes for use of a subset of members in the
library in one or more steps (e.g., a selection step and/or a binding step). In particular embodiments, the
oligonucleotide is a use tag including a use sequence. In some embodiments, an oligonucleotide (e.g., a
headpiece and/or one or more building blocks) encodes for the origin of the member of the library (e.g.,
in a particular part of the library). In some embodiments, the oligonucleotide (e.g., the headpiece, the
first building block tag, the second building block tag, and/or one or more additional building block tags,
if present) includes an origin sequence (e.g., a random degenerate sequence having a length of about 10,
9, 8, 7, or 6 nucleotides), where the sequence encodes for the origin of the member in the library. In
particular embodiments, the oligonucleotide is an origin tag including an origin sequence. In some
embodiments, the method further includes joining, binding, or operatively associating a use tag and/or an
origin tag to the complex.
In any of the above embodiments, the methods, compositions, and complexes optionally include
a tailpiece, where the tailpiece includes one or more of a library-identifying sequence, a use sequence, or
an origin sequence, as described herein. In particular embodiments, the methods further include joining,
binding, or operatively associating the tailpiece (e.g., including one or more of a library-identifying
sequence, a use sequence, or an origin sequence) to the complex.
In any of the above embodiments, the methods, compositions, and complexes, or portions thereof
(e.g., the headpiece, the first building block tag, the second building block tag, and/or the one or more
additional building block tags, if present), includes a modified phosphate group (e.g., a phosphorothioate
or a 5’-N-phosphoramidite linkage) between the terminal nucleotide at the 3’-terminus and the nucleotide
adjacent to the terminal nucleotide. In particular embodiments, the modified phosphate group minimizes
shuffling during enzymatic ligation between two oligonucleotides (e.g., minimizes inclusion of an
additional nucleotide or excision of a nucleotide in the final product or complex, as compared to the
sequences of two oligonucleotides to be ligated, such as between a headpiece to a building block tag or
between a first building block tag and a second building block tag), as compared to ligation between two
oligonucleotides (e.g., a headpiece and a building block tag or a first building block tag and a second
building block tag) lacking the modified phosphate group. In some embodiments, the complex may
include a phosphorothioate or a triazole group.
In any of the above embodiments, the methods, compositions, and complexes, or portions thereof
(e.g., the headpiece, the first building block tag, the second building block tag, and/or the one or more
additional building block tags, if present), includes a modification that supports solubility in semi-,
reduced-, or non-aqueous (e.g., organic) conditions. In some embodiments, the bifunctional linker,
headpiece, or one or more building block tags is modified to increase solubility of a member of said
DNA-encoded chemical library in organic conditions In some embodiments, the modification is one or
more of an alkyl chain, a polyethylene glycol unit, a branched species with positive charges, or a
hydrophobic ring structure. In some embodiments, the modification includes one or more modified
nucleotides having a hydrophobic moiety (e.g., modified at the C5 positions of T or C bases with
aliphatic chains, such as in 5’-dimethoxytrityl-N4-diisobutylaminomethylidene(1-propynyl)-2’-
deoxycytidine,3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 5’-dimethoxytrityl(1-
propynyl)-2’-deoxyuridine,3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 5’-dimethoxytrityl
fluoro-2’-deoxyuridine,3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; and 5’-dimethoxytrityl-
-(pyrenyl-ethynyl)-2’-deoxyuridine, or 3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite) or an
insertion having a hydrophobic moiety (e.g., an azobenzene). In some embodiments, the member of the
library has an octanol:water coefficient from about 1.0 to about 2.5 (e.g., about 1.0 to about 1.5, about 1.0
to about 2.0, about 1.3 to about 1.5, about 1.3 to about 2.0, about 1.3 to about 2.5, about 1.5 to about 2.0,
about 1.5 to about 2.5, or about 2.0 to about 2.5).
In any of the above embodiments, the headpiece, the tailpiece, the first building block tag, the
second building block tag, the one or more additional building block tags, the library-identifying tag, the
use tag, and/or the origin tag, if present, may include from 5 to 20 nucleotides (e.g., from 5 to 7
nucleotides, from 5 to 8 nucleotides, from 5 to 9 nucleotides, from 5 to 10 nucleotides, from 5 to 11
nucleotides, from 5 to 12 nucleotides, from 5 to 13 nucleotides, from 5 to 14 nucleotides, from 5 to 15
nucleotides, from 5 to 16 nucleotides, from 5 to 17 nucleotides, from 5 to 18 nucleotides, from 5 to 19
nucleotides, from 6 to 7 nucleotides, from 6 to 8 nucleotides, from 6 to 9 nucleotides, from 6 to 10
nucleotides, from 6 to 11 nucleotides, from 6 to 12 nucleotides, from 6 to 13 nucleotides, from 6 to 14
nucleotides, from 6 to 15 nucleotides, from 6 to 16 nucleotides, from 6 to 17 nucleotides, from 6 to 18
nucleotides, from 6 to 19 nucleotides, from 6 to 20 nucleotides, from 7 to 8 nucleotides, from 7 to 9
nucleotides, from 7 to 10 nucleotides, from 7 to 11 nucleotides, from 7 to 12 nucleotides, from 7 to 13
nucleotides, from 7 to 14 nucleotides, from 7 to 15 nucleotides, from 7 to 16 nucleotides, from 7 to 17
nucleotides, from 7 to 18 nucleotides, from 7 to 19 nucleotides, from 7 to 20 nucleotides, from 8 to 9
nucleotides, from 8 to 10 nucleotides, from 8 to 11 nucleotides, from 8 to 12 nucleotides, from 8 to 13
nucleotides, from 8 to 14 nucleotides, from 8 to 15 nucleotides, from 8 to 16 nucleotides, from 8 to 17
nucleotides, from 8 to 18 nucleotides, from 8 to 19 nucleotides, from 8 to 20 nucleotides, from 9 to 10
nucleotides, from 9 to 11 nucleotides, from 9 to 12 nucleotides, from 9 to 13 nucleotides, from 9 to 14
nucleotides, from 9 to 15 nucleotides, from 9 to 16 nucleotides, from 9 to 17 nucleotides, from 9 to 18
nucleotides, from 9 to 19 nucleotides, from 9 to 20 nucleotides, from 10 to 11 nucleotides, from 10 to 12
nucleotides, from 10 to 13 nucleotides, from 10 to 14 nucleotides, from 10 to 15 nucleotides, from 10 to
16 nucleotides, from 10 to 17 nucleotides, from 10 to 18 nucleotides, from 10 to 19 nucleotides, from 10
to 20 nucleotides, from 11 to 12 nucleotides, from 11 to 13 nucleotides, from 11 to 14 nucleotides, from
11 to 15 nucleotides, from 11 to 16 nucleotides, from 11 to 17 nucleotides, from 11 to 18 nucleotides,
from 11 to 19 nucleotides, from 11 to 20 nucleotides, from 12 to 13 nucleotides, from 12 to 14
nucleotides, from 12 to 15 nucleotides, from 12 to 16 nucleotides, from 12 to 17 nucleotides, from 12 to
18 nucleotides, from 12 to 19 nucleotides, from 12 to 20 nucleotides, from 13 to 14 nucleotides, from 13
to 15 nucleotides, from 13 to 16 nucleotides, from 13 to 17 nucleotides, from 13 to 18 nucleotides, from
13 to 19 nucleotides, from 13 to 20 nucleotides, from 14 to 15 nucleotides, from 14 to 16 nucleotides,
from 14 to 17 nucleotides, from 14 to 18 nucleotides, from 14 to 19 nucleotides, from 14 to 20
nucleotides, from 15 to 16 nucleotides, from 15 to 17 nucleotides, from 15 to 18 nucleotides, from 15 to
19 nucleotides, from 15 to 20 nucleotides, from 16 to 17 nucleotides, from 16 to 18 nucleotides, from 16
to 19 nucleotides, from 16 to 20 nucleotides, from 17 to 18 nucleotides, from 17 to 19 nucleotides, from
17 to 20 nucleotides, from 18 to 19 nucleotides, from 18 to 20 nucleotides, and from 19 to 20
nucleotides). In particular embodiments, the headpiece, the first building block tag, the second building
block tag, the one or more additional building block tags, the library-identifying tag, the use tag, and/or
the origin tag, if present, have a length of less than 20 nucleotides (e.g., less than 19 nucleotides, less than
18 nucleotides, less than 17 nucleotides, less than 16 nucleotides, less than 15 nucleotides, less than 14
nucleotides, less than 13 nucleotides, less than 12 nucleotides, less than 11 nucleotides, less than 10
nucleotides, less than 9 nucleotides, less than 8 nucleotides, or less than 7 nucleotides).
In particular embodiments, the first building block tag and the second building block tag include
the same number of nucleotides. In other embodiments, either the first building block tag or the second
building block tag includes more than 8 nucleotides (e.g., more than 9 nucleotides, more than 10
nucleotides, more than 11 nucleotides, more than 12 nucleotides, more than 13 nucleotides, more than 14
nucleotides, and more than 15 nucleotides). In some embodiments, the first building block tag is a donor
tag (e.g., as defined herein) having from 8 to 20 nucleotides (e.g., from 8 to 9 nucleotides, from 8 to 10
nucleotides, from 8 to 11 nucleotides, from 8 to 12 nucleotides, from 8 to 13 nucleotides, from 8 to 14
nucleotides, from 8 to 15 nucleotides, from 8 to 16 nucleotides, from 8 to 17 nucleotides, from 8 to 18
nucleotides, from 8 to 19 nucleotides, from 8 to 20 nucleotides, from 9 to 10 nucleotides, from 9 to 11
nucleotides, from 9 to 12 nucleotides, from 9 to 13 nucleotides, from 9 to 14 nucleotides, from 9 to 15
nucleotides, from 9 to 16 nucleotides, from 9 to 17 nucleotides, from 9 to 18 nucleotides, from 9 to 19
nucleotides, from 9 to 20 nucleotides, from 10 to 11 nucleotides, from 10 to 12 nucleotides, from 10 to 13
nucleotides, from 10 to 14 nucleotides, from 10 to 15 nucleotides, from 10 to 16 nucleotides, from 10 to
17 nucleotides, from 10 to 18 nucleotides, from 10 to 19 nucleotides, from 10 to 20 nucleotides, from 11
to 12 nucleotides, from 11 to 13 nucleotides, from 11 to 14 nucleotides, from 11 to 15 nucleotides, from
11 to 16 nucleotides, from 11 to 17 nucleotides, from 11 to 18 nucleotides, from 11 to 19 nucleotides,
from 11 to 20 nucleotides, from 12 to 13 nucleotides, from 12 to 14 nucleotides, from 12 to 15
nucleotides, from 12 to 16 nucleotides, from 12 to 17 nucleotides, from 12 to 18 nucleotides, from 12 to
19 nucleotides, from 12 to 20 nucleotides, from 13 to 14 nucleotides, from 13 to 15 nucleotides, from 13
to 16 nucleotides, from 13 to 17 nucleotides, from 13 to 18 nucleotides, from 13 to 19 nucleotides, from
13 to 20 nucleotides, from 14 to 15 nucleotides, from 14 to 16 nucleotides, from 14 to 17 nucleotides,
from 14 to 18 nucleotides, from 14 to 19 nucleotides, from 14 to 20 nucleotides, from 15 to 16
nucleotides, from 15 to 17 nucleotides, from 15 to 18 nucleotides, from 15 to 19 nucleotides, from 15 to
nucleotides, from 16 to 17 nucleotides, from 16 to 18 nucleotides, from 16 to 19 nucleotides, from 16
to 20 nucleotides, from 17 to 18 nucleotides, from 17 to 19 nucleotides, from 17 to 20 nucleotides, from
18 to 19 nucleotides, from 18 to 20 nucleotides, and from 19 to 20 nucleotides).
Definitions
By “2’-substituted nucleotide” is meant a nucleotide base having a substitution at the 2’-position
of ribose in the base.
By “about” is meant +/- 10% of the recited value.
By “bifunctional” is meant having two reactive groups that allow for binding of two chemical
moieties. For example, a bifunctional linker is a linker, as described herein, having two reactive groups
that allow for binding of a headpiece and a chemical entity
By “binding” is meant attaching by a covalent bond or a non-covalent bond. Non-covalent bonds
include those formed by van der Waals forces, hydrogen bonds, ionic bonds, entrapment or physical
encapsulation, absorption, adsorption, and/or other intermolecular forces. Binding can be effectuated by
any useful means, such as by enzymatic binding (e.g., enzymatic ligation) or by chemical binding (e.g.,
chemical ligation).
By “building block” is meant a structural unit of a chemical entity, where the unit is directly
linked to other chemical structural units or indirectly linked through the scaffold. When the chemical
entity is polymeric or oligomeric, the building blocks are the monomeric units of the polymer or
oligomer. Building blocks can have one or more diversity nodes that allow for the addition of one or
more other building blocks or scaffolds. In most cases, each diversity node is a functional group capable
of reacting with one or more building blocks or scaffolds to form a chemical entity. Generally, the
building blocks have at least two diversity nodes (or reactive functional groups), but some building
blocks may have one diversity node (or reactive functional group). Alternatively, the encoded chemical
or binding steps may include several chemical components (e.g., multi-component condensation reactions
or multi-step processes). Reactive groups on two different building blocks should be complementary, i.e.,
capable of reacting together to form a covalent or a non-covalent bond.
By “building block tag” is meant an oligonucleotide portion of the library that encodes the
addition (e.g., by a binding reaction) of a component (i.e., a scaffold or a building block), the headpiece in
the library, the identity of the library, the use of the library, and/or the origin of a library member. By
“acceptor tag” is meant a building block tag having a reactive entity (e.g., a hydroxyl group at the 3’-
terminus in the case of enzymatic ligation). By “donor tag” is meant a building block tag having an entity
capable of reacting with the reactive entity on the acceptor tag (e.g., a phosphoryl group at the 5’-
terminus in the case of enzymatic ligation).
By “chemical entity” is meant a compound comprising one or more building blocks and
optionally a scaffold. The chemical entity can be any small molecule or peptide drug or drug candidate
designed or built to have one or more desired characteristics, e.g., capacity to bind a biological target,
solubility, availability of hydrogen bond donors and acceptors, rotational degrees of freedom of the
bonds, positive charge, negative charge, and the like. In certain embodiments, the chemical entity can be
reacted further as a bifunctional or trifunctional (or greater) entity.
By “chemically co-reactive pair” is meant a pair of reactive groups that participates in a modular
reaction with high yield and a high thermodynamic gain, thus producing a spacer. Exemplary reactions
and chemically co-reactive pairs include a Huisgen 1,3-dipolar cycloaddition reaction with a pair of an
optionally substituted alkynyl group and an optionally substituted azido group; a Diels-Alder reaction
with a pair of an optionally substituted diene having a 4 π electron system and an optionally substituted
dienophile or an optionally substituted heterodienophile having a 2 π electron system; a ring opening
reaction with a nucleophile and a strained heterocyclyl electrophile; a splint ligation reaction with a
phosphorothioate group and an iodo group; and a reductive amination reaction with an aldehyde group
and an amino group, as described herein.
By “complex” or “ligated complex” is meant a headpiece that is operatively associated with a
chemical entity and/or one or more oligonucleotide tags by a covalent bond or a non-covalent bond. The
complex can optionally include a bifunctional linker between the chemical entity and the headpiece.
By “component” of a chemical entity is meant either a scaffold or a building block.
By “diversity node” is meant a functional group at a position in the scaffold or the building block
that allows for adding another building block.
By “headpiece” is meant a starting oligonucleotide for library synthesis that is operatively linked
to a component of a chemical entity and to a building block tag. Optionally, a bifunctional linker
connects the headpiece to the component.
By “library” is meant a collection of molecules or chemical entities. Optionally, the molecules or
chemical entities are bound to one or more oligonucleotides that encodes for the molecules or portions of
the chemical entity.
By “linker” is meant a chemical connecting entity that links the headpiece to a chemical entity.
By “multivalent cation” is meant a cation capable of forming more than one bond with more than
one ligand or anion. The multivalent cation can form either an ionic complex or a coordination complex.
Exemplary multivalent cations include those from the alkali earth metals (e.g., magnesium) and transition
metals (e.g., manganese (II) or cobalt (III)), and those that are optionally bound to one or more anions
and/or one or more univalent or polydentate ligands, such as chloride, amine, and/or ethylenediamine.
By “oligonucleotide” is meant a polymer of nucleotides having a 5’-terminus, a 3’-terminus, and
one or more nucleotides at the internal position between the 5’- and 3’-termini. The oligonucleotide may
include DNA, RNA, or any derivative thereof known in the art that can be synthesized and used for base-
pair recognition. The oligonucleotide does not have to have contiguous bases but can be interspersed
with linker moieties. The oligonucleotide polymer may include natural bases (e.g., adenosine, thymidine,
guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, deoxycytidine, inosine,
or diamino purine), base analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine,
3-methyl adenosine, C5-propynylcytidine, C5-propynyluridine, C5-bromouridine, C5-fluorouridine,
C5-iodouridine, C5-methylcytidine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine,
8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine), modified nucleotides (e.g., 2’-substituted
nucleotides, such as 2’-O-methylated bases and 2’-fluoro bases), intercalated bases, modified sugars (e.g.,
2’-fluororibose, ribose, 2’-deoxyribose, arabinose, and hexose), and/or modified phosphate groups (e.g.,
phosphorothioates and 5’-N-phosphoramidite linkages). Other modified bases are described herein. By
“acceptor oligonucleotide” is meant an oligonucleotide having a reactive entity (e.g., a hydroxyl group at
the 3’-terminus in the case of enzymatic ligation or an optionally substituted azido group in the case of
chemical ligation). By “donor oligonucleotide” is meant an oligonucleotide having an entity capable of
reacting with the reactive entity on the acceptor oligonucleotide (e.g., a phosphoryl group at the 5’-
terminus in the case of enzymatic ligation or an optionally substituted alkynyl group in the case of
chemical ligation).
By “operatively linked” or “operatively associated” is meant that two or more chemical structures
are directly or indirectly linked together in such a way as to remain linked through the various
manipulations they are expected to undergo. Typically, the chemical entity and the headpiece are
operatively linked in an indirect manner (e.g., covalently via an appropriate linker). For example, the
linker may be a bifunctional moiety with a site of attachment for chemical entity and a site of attachment
for the headpiece. In addition, the chemical entity and the oligonucleotide tag can be operatively linked
directly or indirectly (e.g., covalently via an appropriate linker).
By “protecting group” is a meant a group intended to protect the 3’-terminus or 5’-terminus of an
oligonucleotide against undesirable reactions during one or more binding steps of tagging a DNA-
encoded library. Commonly used protecting groups are disclosed in Greene, “Protective Groups in
Organic Synthesis,” 4 Edition (John Wiley & Sons, New York, 2007), which is incorporated herein by
reference. Exemplary protecting groups include irreversible protecting groups, such as
dideoxynucleotides and dideoxynucleosides (ddNTP or ddN), and, more preferably, reversible protecting
groups for hydroxyl groups, such as ester groups (e.g., O-( α-methoxyethyl)ester, O-isovaleryl ester, and
O-levulinyl ester), trityl groups (e.g., dimethoxytrityl and monomethoxytrityl), xanthenyl groups (e.g., 9-
phenylxanthenyl and 9-(p-methoxyphenyl)xanthenyl), acyl groups (e.g., phenoxyacetyl and acetyl),
and silyl groups (e.g., t-butyldimethylsilyl).
By “purifying” is meant removing any unreacted product or any agent present in a reaction
mixture that may reduce the activity of a chemical or biological agent to be used in a successive step.
Purifying can include one or more of chromatographic separation, electrophoretic separation, and
precipitation of the unreacted product or reagent to be removed.
By “scaffold” is meant a chemical moiety that displays one or more diversity nodes in a
particular special geometry. Diversity nodes are typically attached to the scaffold during library
synthesis, but in some cases one diversity node can be attached to the scaffold prior to library synthesis
(e.g., addition of one or more building blocks and/or one or more tags). In some embodiments, the
scaffold is derivatized such that it can be orthogonally deprotected during library synthesis and
subsequently reacted with different diversity nodes.
By “small molecule” drug or “small molecule” drug candidate is meant a molecule that has a
molecular weight below about 1,000 Daltons. Small molecules may be organic or inorganic, isolated
(e.g., from compound libraries or natural sources), or obtained by derivatization of known compounds.
By “substantial identity” or “substantially identical” is meant a polypeptide or polynucleotide
sequence that has the same polypeptide or polynucleotide sequence, respectively, as a reference sequence,
or has a specified percentage of amino acid residues or nucleotides, respectively, that are the same at the
corresponding location within a reference sequence when the two sequences are optimally aligned. For
example, an amino acid sequence that is “substantially identical” to a reference sequence has at least
50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the reference
amino acid sequence. For polypeptides, the length of comparison sequences will generally be at least 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous amino acids, more preferably at least 25,
50, 75, 90, 100, 150, 200, 250, 300, or 350 contiguous amino acids, and most preferably the full-length
amino acid sequence. For nucleic acids, the length of comparison sequences will generally be at least 5
contiguous nucleotides, preferably at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25
contiguous nucleotides, and most preferably the full length nucleotide sequence. Sequence identity may
be measured using sequence analysis software on the default setting (e.g., Sequence Analysis Software
Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710
University Avenue, Madison, WI 53705). Such software may match similar sequences by assigning
degrees of homology to various substitutions, deletions, and other modifications.
By “tailpiece” is meant an oligonucleotide portion of the library that is attached to the complex
after the addition of all of the building block tags and encodes for the identity of the library, the use of the
library, and/or the origin of a library member.
Other features and advantages of the invention will be apparent from the following Detailed
Description and the claims.
Brief Description of the Drawings
Figure 1 shows an exemplary method for the general synthesis of chemical libraries using single-
stranded DNA tags that are joined sequentially by means of enzymatic and/or chemical ligation. “BB”
refers to building block.
Figures 2A-2B show exemplary methods for single-stranded DNA tagging of libraries using
enzymatic ligation. Figure 2A shows an exemplary method for tagging libraries using single-stranded
enzymatic ligation with a protected (re-installed) 5’-monophosphate (5’-P) oligonucleotide, where gray
boxes refer to 2’-OMe nucleotides, “X” refers to a protecting group or a component of a chemical entity,
and “PNK” refers to polynucleotide kinase. Figure 2B shows an exemplary method for tagging libraries
using single-stranded ligation with a protected 3’-OH oligonucleotide, where black boxes attached to -O-
refer to a protecting group of the 3’-OH terminus and “LC” refers to liquid chromatographic separation of
the protecting group.
Figure 3 shows an exemplary method for tagging libraries using single-stranded ligation with a
’-preadenylated (labeled “5’-App”) oligonucleotide (headpiece) with a 3’-terminus that is blocked, e.g.,
by a chemical entity (labeled “X-3’”). This method can be used to ligate a 5’-phosphorylated
oligonucleotide tag (labeled “Tag A”) to the headpiece and additional tags having a 3’-OH terminus
(labeled “Tag B” and “Tag C”) to the complex in the presence of ATP.
Figures 4A-4E show exemplary complexes, each having a headpiece, a linker, and a small
molecule including a scaffold (“S”) and diversity nodes A, B, and C. The dark gray boxes refer to 2’-
OMe nucleotides, and the dotted lines refer to the presence of one or more complementary bases. Figures
4A-4B are schematics for complexes having a single-stranded linear oligonucleotide headpiece, where the
linker and small molecule are connected to the 3’-terminus (Figure 4A) or the 5’-terminus (Figure 4B) of
the headpiece. Figures 4C-4D are schematics for complexes having a single-stranded hairpin
oligonucleotide headpiece, where the linker and small molecule are connected to the internal position
(Figure 4C) or the 3’-terminus (Figure 4D) of the headpiece. Figure 4E shows an exemplary method for
tagging libraries having a hairpin oligonucleotide headpiece, where the star refers to a chemical moiety
and “Y” at the 3’-terminus refers to a protecting group. Oligonucleotide tags are labeled 1-4, and the
adapter sequence is the black line at the 5’-terminus.
Figures 5A-5C show oligonucleotide ligation by T4 RNA ligase or CircLigase™ ssDNA ligase.
Figure 5A is a schematic of the enzymatic ligation reaction. The donor oligonucleotide is 5’-
phosphorylated and carries a 3’-fluorescein label, imitating a headpiece with a chemical library at 3’ end.
The acceptor oligonucleotide is not phosphorylated. Figure 5B shows gel electrophoresis analysis of a
ligation reaction on an 8M urea/ 15% polyacrylamide gel (PAAG). “SM” refers to fluorescently labeled
donor, “Product” refers to ligation product, and “Adenylated donor” refers to 5’App-Donor, as described
above. Figure 5C shows high yield ligation achieved for T4 RNA ligase at high enzyme and
oligonucleotide concentrations.
Figures 6A-6B represent optimization of PEG molecular weight (Figure 6A) and concentration
(Figure 6B) to achieve maximal ligation yield by T4 RNA ligase. Reaction conditions are as described
above for Figures 5A-5C. Figure 6A is graph quantifying the electrophoretic analysis of a ligation
reaction with MNA/DNA 15mer donor and acceptor tags after incubation for 5 hours or 20 hours with
% (w/v) PEG having a molecular weight from 300 to 20,000 (20K). Figure 6B shows the effect of
concentration on ligation after incubation for 18-20 hours in the presence of 5% to 45% (w/v) of
PEG4600.
Figures 7A-7B show a correlation between ligation efficiency by CircLigase™ (Figure 7A) and
T4 RNA ligase (Figure 7B) and length of the donor or acceptor oligonucleotides. Figure 7A depicts a
graph quantifying the effect of the acceptor length on ligation yield in the CircLigase™ ligation reaction.
Figure 7B depicts a graph and a table quantifying the effect of nucleotide length of the acceptor and
donor MNA/DNA tags on single-stranded ligation with T4 RNA ligase. These data represent an average
of two independent experiments obtained by densitometry of fluorescent gels at 450 nm excitation.
Figures 8A-8B are LC-MS spectra for a MNA/DNA tag before and after phosphorylation. Data
are shown for 15mer tag 5’-HO-mUAC GTA TAC GAC TGmG-OH-3’ (SEQ ID NO: 13) (at 250 μM)
before (Figure 8A) and after (Figure 8B) reaction with T4 polynucleotide kinase (50 units per 5 nmole of
tag).
Figure 9 shows an electrophoretic gel for sequential single-stranded ligation of tags A-C. The
3’-terminus included fluorescein to represent a library compound (or chemical entity), and the asterisk (*)
indicates purification of the ligated product (or complex) prior to phosphorylation.
Figures 10A-10B show schematics of a “chemically co-reactive pair” reaction between donor
and acceptor oligonucleotides resulting in a 5-atom “short” spacer (Figure 10A) and a 24-atom “long”
spacer (Figure 10B).
Figures 11A-11E show results of reverse transcription (RT) and PCR analysis of 75mer DNA
templates containing a short or a long single spacer, as depicted in Figures 10A-10B. Figure 11A is a
schematic of the RT reaction. LC-MS spectra of the RT were recorded at both 260 nm and 650 nm for
the control 75mer DNA template (Figure 11B), the 75mer DNA template containing a single 5-atom
(“short”) spacer (Figure 11C), and the 75mer DNA template containing a single 24-atom (“long”) spacer
(Figure 11D). Figure 11E shows RT-PCR analysis of the control 75mer DNA template (“templ75”), a
75mer DNA template with a 5-atom spacer (“short click”), and a 75mer DNA template with a 24-atom
spacer (“long click”).
Figures 12A-12G show the results of a chemical ligation reaction between a 5’-iodo-modified
DNA oligonucleotide and a 3’-phosphorothioate DNA oligonucleotide in the presence or absence of a
complementary splint oligonucleotide. Figure 12A shows an exemplary schematic of the reaction. The
’-iodo oligonucleotide is labeled with 6-FAM at 3’-terminus, while the 3’-phosphorothioate
oligonucleotide is labeled with Cy5 at the 5’-terminus. Figure 12B shows a gel electrophoresis analysis
of the ligation reactions in the presence (+spl) or absence (-spl) of a complementary splint. CCy5 and
CFL indicate visible bands of Cy5 and fluorescein-labeled starting material, respectively. Figure 12C
shows a time course of the splinted ligation reaction under the above conditions, which was quantified
using Cy5 (635 nm) and fluorescein (450 nm) detection. Figure 12D shows LC-MS analysis of the
ligation of CFL and CCy5 in the absence (top, at 260 nm, 495 nm, and 650 nm) and presence (bottom, at
260 nm, 495 nm, and 650 nm) of a splint, where ligation reactions were incubated for seven days. Figure
12E shows LC-MS analysis of the ligation of CFL and CCy5 in the absence a splint (at 260 nm, 495 nm,
and 650 nm), where ligation reactions were incubated for eight days. Figure 12F shows MS analysis of
reaction of CFL oligonucleotide with piperidine, where this reaction was intended to displace iodine.
Reaction conditions included oligonucleotides at 100 µM, piperidine at 40 mM (400 equivalents) in 100
mM borate buffer, pH 9.5, for 20 hrs at room temperature (left); and oligonucleotides at 400 µM,
piperidine at 2 M (4,000 equivalents) in 200 mM borate buffer, pH 9.5, for 2 hrs at 65°C (right). Figure
12G shows MS analysis of a splinted ligation reaction of CFL and CCy5 oligonucleotides at 50 µM
performed in the presence of 400 equivalents of piperidine in 100 mM borate buffer, pH 9.5, for 20 hrs at
room temperature.
Figures 13A-13C shows the use of modified oligonucleotides to minimize shuffling. Figure 13A
shows an LC-MS analysis of a single-stranded ligation reaction of a 5’-phosphorylated headpiece ssHP
(3,636 Da) and a tag (tag 15; 2,469 Da) having 2’-O methyl nucleotides. The LC-MS analysis showed
three peaks: peak 1 for the tag (2,469 Da); peak 2 for the adenylated headpiece (3,965 Da); and peak 3
having two (in some instances three) sub-peaks containing products with molecular weights of 6,089 Da
(expected ligation product); 5,769 Da (expected 6,089 Da -320 Da); and 6,409 Da (expected 6,089 Da +
320 Da). This mass difference of 320 Da corresponds exactly to either removal or addition of an extra 2’-
O-Me C nucleotide. Figures 13B-1 to 13B-3 show a non-limiting, proposed mechanism of the nucleotide
shuffling, where about 90% of the reaction provides the expected (normal) ligation product and about
10% of the reaction provides aberrant ligation products (“Product -1 nt” and “Product + 1 nt”). Figure
13C shows an LC-MS analysis of ligation of headpiece HP-PS with tag 15. The headpiece HP-PS has the
sequence the headpiece ssHP but includes a phosphorothioate linkage at the 5’-terminus. LC analysis
showed three peaks: peak 1 for the tag (2,469), peak 2 for the adenylated headpiece (3,984), and peak 3
for a single ligation product (6,107) with almost no nucleotide shuffling observed. Traces of +/- 320
peaks likely correspond to the oxidative conversion of the phosphorothioate linkage into a native
phosphodiester linkage or are due to incomplete sulfurization.
Figure 14 is a graph showing separation of library members using size exclusion
chromatography, where target-bound library members (left on graph) elute at a shorter time than unbound
library members (right on graph).
Figure 15A is an exemplary schematic showing the chemical ligation of encoding DNA tags
using a single chemistry that is not splint-dependent, e.g. 5’-azido/3’-alkynyl. The reactive groups are
present on the 3’ and 5’ ends of each tag (Tag A, B, and C), and one of the reactive groups on either end
(for example, the 3’ end) is protected to prevent the cyclization, polymerization, or wrong-cycle ligation
of the tags. The cycle of tag ligation includes chemical ligation, followed by deprotection of the
remaining functional group to render the growing ligated entity competent for the next cycle of ligation.
Each cycle also includes addition of one or more building blocks (BBA, BBB, and BBC, which are
encoded by Tag A, B, and C, respectively). The chemical ligation process can optionally include addition
of a tailpiece.
Figure 15B is an exemplary schematic showing the chemical ligation of encoding DNA tags
using a single chemistry that is splint-dependent. The template-dependent nature of this approach reduces
the frequency of occurrence of tag polymerization, tag cyclization, as well as of mistagging events.
Similar to Figure 15A, this schematic includes tags (Tag A, B, and C) and one or more building blocks
encoded by tags (BBA, BBB, and BBC).
Figure 15C is an exemplary schematic showing the use of a succession of chemically ligated tags
as a template for template-dependent polymerization, generating cDNA that is competent for PCR
amplification and sequencing, as well as using a template-dependent polymerase capable of reading
through the chemically ligated junctions.
Figure 16A is an exemplary schematic showing the chemical ligation of encoding DNA tags
using TIPS-protected alkynyl tags and “click” chemistry. Each cycle of library synthesis includes Cu(I)-
catalyzed chemical ligation of the TIPS-protected tag to the deprotected alkyne from the previous cycle.
After the ligation, the TIPS group is removed (deprotected), thereby activating the alkyne for the next
chemical ligation step.
Figure 16B shows the structure of DMT-succinyl-3’-O-TIPS-propargyl uridine CPG that is used
to initiate solid-phase synthesis of oligonucleotides bearing 3’-O-TIPS-propargyl uridine at the 3’-
terminus.
Figure 16C is an exemplary schematic showing the use of a succession of “click” chemically
ligated tags as a template for template-dependent polymerization, generating cDNA that is competent for
PCR amplification and sequencing, as well as using a template-dependent polymerase capable of reading
through the “click” chemically ligated junctions.
Figures 17A-17C show the synthesis of 5’-biotinylated, “single-click” templates Y55 and Y185.
Figure 17A provides an exemplary schematic. Figure 17B and Figure 17C show
LC-MS analysis of Y55 and Y185, respectively.
Figures 18A-18C provide an exemplary assay for the “read-through” of a “single-click”
template. Figure 18A shows a schematic, where FAM-labeled primer is annealed to the biotinylated
template and is incubated with the template-dependent polymerase, according to the manufacturer’s
recommended conditions. The complexes are subsequently incubated with streptavidin beads, washed,
eluted with NaOH, and then neutralized. After neutralization the samples are analyzed by LC-MS.
Figure 18B and Figure 18C show LC-MS data of the Klenow fragment copying of templates Y55 and
Y185, respectively.
Figures 19A-19D provides the synthesis of 5’-biotinylated “double-click” template YDC and
“triple-click template” YTC using a TIPS-protected alkynyl tag. Figures 19A and 19B show exemplary
schematics for this synthesis. Figures 19C and 19D show LC-MS analysis of the YDC and YTC
templates respectively.
Figures 20A-20C provide an exemplary click “read-through” assay using “double-click” and
“triple-click” templates. Figure 20A is a schematic, where FAM-labeled primer is annealed to the
biotinylated template and is incubated with Klenow fragment of E.coli DNA polymerase I according to
the manufacturer’s recommended reaction conditions. The complexes are incubated with streptavidin
beads, washed, eluted with NaOH, and neutralized. After the neutralization, the samples are assayed by
LC-MS. Figures 20B and 20C show LC-MS data of the Klenow fragment copying of the templates YDC
and YTC, respectively.
Figure 21 is a graph showing the efficiency of the click “read-through” using “single-click”,
“double-click” and “triple-click” templates in comparison to a control “no-click” DNA template. These
data were obtained using the “read-through” assay described herein, and the yields were measured by LC
MS analysis by comparison to an internal standard.
Figures 22A-22C provide exemplary schematics of chemical ligation with orthogonal chemistry.
Figure 22A is a schematic of the chemical ligation strategy for DNA encoding tags that (i) utilizes two
successive orthogonal chemistries for (ii) available read-through strategies. Each tag contains two
orthogonal reactive groups, indicated by differing symbols for the 5’-terminus and the 3’-terminus of
each tag. In each successive cycle of chemical ligation, an orthogonal chemistry is used. This strategy
reduces the frequency of occurrence of mistagging events and may also be used without the protection of
the reactive terminal groups. Figure 22B is a schematic of the template-dependent polymerization “read-
though” of a template generated by the orthogonal chemical ligation of orthogonal DNA tags to generate
cDNA from which the sequence of the tags can be deduced. Figure 22C is the same as Figure 22B but
includes a self-priming tailpiece, which may be rendered double-stranded by restriction digestion to
facilitate strand-separation during PCR amplification.
Figure 23 is an exemplary schematic showing the chemical ligation strategy for DNA encoding
tags that utilizes two specific successive orthogonal chemistries. Each tag contains click-reactive and
phosphorothioate/iodo-reactive groups. Tags bearing orthogonal reactive groups at their 3’ and 5’ ends
cannot polymerize and have a reduced frequency of occurrence of mistagging events. Without wishing to
be limited, this approach may eliminate the need for the TIPS-protection of the 3’-alkyne. In cycle A, the
’-iodo/3’-alkynyl tag is ligated using splint-dependent ligation to the 3’-phosphorothioate headpiece,
leaving a reactive 3’ alkyne for the next cycle of chemical ligation to a 5’-azido/3’-phosphorothioate tag.
The orthogonal ligation cycles may be repeated as many times as is desired.
Figures 24A-24B show the protection and use of 3’-phosphorothioate/5’-iodo groups on DNA
tags. Figure 24A shows an exemplary schematic for using protecting groups (PG) for these tags. Figure
24B shows an exemplary scheme for use of 3’-phosphorothioate/5’-iodo tags to chemically ligate
succession of encoding DNA tags that encode a chemical library covalently installed upon the 5’-
terminus.
Figures 25A-25B show the protection and use of 3’-phosphorothioate groups on DNA tags.
Figure 25A shows the scheme for protection of these groups. Figure 25B shows the scheme for use of 3’-
phosphorothioate/5’-azido and 3’-propargyl/5’-iodo tags to chemically ligate a succession of orthogonal
encoding DNA tags that encode a chemical library covalently installed upon the 5’-terminus.
Detailed Description
Described herein are methods of using single-stranded ligation to install oligonucleotide tags onto
chemical entity-oligonucleotide complexes. This method can be used to create diverse libraries of
selectable chemical entities by establishing an encoded relationship between particular tags and particular
chemical reactions or building blocks. To identify one or more chemical entities, the oligonucleotide tags
can be amplified, cloned, sequenced, and correlated by using the established relationship. In particular,
reaction conditions that promote single-stranded ligation of tags were identified. These conditions
include the use of one or more 2’-substituted nucleotides (e.g., 2’-O-methyl nucleotides or 2’-fluoro
nucleotides) within the tags, the use of tags of particular length (e.g., between 5 and 15 nucleotides), the
use of one or more enzymes (e.g., RNA ligase and/or DNA ligase), and/or the use of one or more agents
during ligation (e.g., poly ethylene glycol and/or a soluble multivalent cation, such as Co(NH ) Cl ).
3 6 3
These methods additionally include methods of chemically joining oligonucleotides, such that the
sequence of the joined oligonucleotide product may be utilized as a template for a template-dependent
polymerase reaction. Methods of creating and tagging libraries of these complexes are described in detail
below.
Methods for tagging encoded libraries
Also described herein is a method for operatively linking oligonucleotide tags with chemical
entities, such that encoding relationships may be established between the sequence of the tag and the
structural units (or building blocks) of the chemical entity. In particular, the identity and/or history of a
chemical entity can be inferred from the sequence of bases in the oligonucleotide. Using this method, a
library including diverse chemical entities or members (e.g., small molecules or peptides) can be
addressed with a particular tag sequence.
Generally, these methods include the use of a headpiece, which has at least one functional group
that may be elaborated chemically and at least one functional group to which a single-stranded
oligonucleotide may be bound (or ligated). Binding can be effectuated by any useful means, such as by
enzymatic binding (e.g., ligation with one or more of an RNA ligase and/or a DNA ligase) or by chemical
binding (e.g., by a substitution reaction between two functional groups, such as a nucleophile and a
leaving group).
To create numerous chemical entities within the library, a solution containing the headpiece can
be divided into multiple aliquots and then placed into a multiplicity of physically separate compartments,
such as the wells of a multiwell plate. Generally, this is the “split” step. Within each compartment or
well, successive chemical reaction and ligation steps are performed with a single-stranded tag within each
aliquot. The relationship between the chemical reaction conditions and the sequence of the single-
stranded tag are recorded. The reaction and ligation steps may be performed in any order. Then, the
reacted and ligated aliquots are combined or “pooled,” and optionally purification may be performed at
this point. These split and pool steps can be optionally repeated.
Next, the library can be tested and/or selected for a particular characteristic or function, as
described herein. For example, the mixture of tagged chemical entities can be separated into at least two
populations, where the first population binds to a particular biological target and the second population
does not. The first population can then be selectively captured (e.g., by eluting on a column providing the
target of interest or by incubating the aliquot with the target of interest) and, optionally, further analyzed
or tested, such as with optional washing, purification, negative selection, positive selection, or separation
steps.
Finally, the chemical histories of one or more members (or chemical entities) within the selected
population can be determined by the sequence of the operatively linked oligonucleotide. Upon
correlating the sequence with the particular building block, this method can identify the individual
members of the library with the selected characteristic (e.g., an increased tendency to bind to the target
protein and thereby elicit a therapeutic effect). For further testing and optimization, candidate therapeutic
compounds may then be prepared by synthesizing the identified library members with or without their
associated oligonucleotide tags.
Figures 1-3 provide various exemplary methods for tagging libraries using single-stranded
ligation with a headpiece, where tags can be ligated on the 5’-terminus or the 3’-terminus of the
headpiece. To control the order in which the tags are ligated and to reduce side reactions, these methods
ensure that only one reactive 5’-terminus and one reactive 3’-terminus are present during ligation.
Furthermore, these exemplary methods use 2’-substituted nucleotides (e.g., mixed 2’-deoxy/2’-O-methyl
nucleotides) in the tags, and these tags act as templates for a DNA- or RNA-dependent polymerase
capable of polymerizing nucleotides in a template-dependent fashion. Without wishing to be limited by
theory, the use of one or more 2’-substituted nucleotides (e.g., 2’-O-methyl nucleotides and/or 2’-fluoro
nucleotides) within a tag could promote ligation by RNA ligase by more closely resembling RNA, while
preserving both the physical and chemical robustness of the recording medium as well as the ability to
extract sequence information using template-dependent polymerization.
Figure 1 provides an exemplary method for reducing side reactions, where the ligated complex
and tags are designed to avoid unwanted reactions between reactive 3’-OH and 5’-monophosphate (“5’-
P”) groups. In particular, this scheme depicts the phosphorylation-ligation cycle approach. During
ligation, only one 3’-OH group (in the tag) and one 5’-P group (in the headpiece) are available, and, thus,
only one ligation event is possible. Following the ligation and purification steps, a 5’-OH group is
formed in the complex, and this group can be converted into a 5’-P for adding subsequent oligonucleotide
tags. The 3’-terminus of the complex is blocked by X, which can be a protecting group or a component
of a chemical entity (e.g., optionally including a linker that acts as a spacer between the chemical entity
and the headpiece).
As shown in Figure 1, the exemplary method includes ligation of building block tag 1 (“tag 1”) to
the 5’-terminus of the headpiece, thereby creating a complex, and performing successive ligations to the
’-terminus of the complex. The reactive 5’-terminus is a phosphate group on the complex, and the
reactive 3’-terminus is a hydroxyl group on the tags. After the addition of each tag, the ligated complex
is separated from the unreacted, unligated headpiece and tags and from other reagents (e.g., phosphate,
cobalt, or other reagents present during the ligation step). Separation can be accomplished by any useful
method (e.g., by chromatographic or electrophoretic separation of ligated and non-ligated products or by
precipitation of a reagent). Then, the ligated complex is exposed to an agent (e.g., a polynucleotide
kinase or a chemical phosphorylating agent) to form a phosphate group on the 5’-terminus of the
complex. The separation and phosphorylation steps may be performed in either order. In particular, if a
kinase is used in the phosphorylation step, the kinase should be inactivated or removed prior to the
addition of the subsequent tags that may also contain a 5’-OH group, or any reagents that can inhibit the
kinase should be removed from the reaction mixture prior to the phosphorylation step.
In another embodiment, the method includes binding successive tags from the 3’-terminus of the
preceding ligated complex. In this method, the ligated complex lacks a reactive 3’-OH group
immediately after the ligation step but contains a group that can be converted into a 3’-OH group (e.g., by
release of a protecting group). Figure 2A provides a schematic showing an exemplary method for tagging
the 3’-terminus of a complex, and Figure 2B provides an exemplary reaction scheme for a protected 3’-
terminus that contains convertible 3’-OH group upon release of the 3’-linked protecting group. As shown
in Figure 2A, building block tag 1 (“tag 1”) has a 3’-protected group. In the first step, the exemplary
method includes ligation of the tag to the 3’-terminus of the headpiece, thereby creating a complex.
Successive ligations are performed to the 3’-terminus of the complex. The reactive 5’-terminus is a
phosphate group on the tag, and the reactive 3’-terminus is a hydroxyl group on the complex. After the
addition of each tag, the ligated complex is deprotected (e.g., by the addition of a hydrolyzing agent) to
release the 3’-protecting group.
In yet another embodiment, the method includes binding successive tags by using a 5’-
preadenylated (5’-App) oligonucleotide and a ligase (e.g., T4 RNA ligase). In the presence of ATP, T4
RNA ligase will use the ATP cofactor to form an adenylated intermediate prior to ligation. In the absence
of ATP, T4 RNA ligase will only ligate preadenylated oligonucleotides, and possible side reactions with
’-P oligonucleotides will not occur. Thus, single-stranded ligation with reduced side reactions can be
performed with a chemically synthesized 5’-App oligonucleotide in the presence of 5’-
monophosphorylated tag, where the 5’-App oligonucleotide can be ligated to a headpiece prior to tagging
or to a complex formed after multiple rounds of tagging.
Figure 3 provides a schematic showing an exemplary method for tagging the 5’-terminus of a
preadenylated headpiece. Adenylation of the donor nucleotide at the 5’-phosphate group is the first step
in the ligation reaction, and this reaction generally requires one molecule of ATP. In the second step, the
3’-OH group of the acceptor oligonucleotide reacts with the adenylated donor and forms a diester bond
between two oligonucleotides, thus releasing one AMP molecule. The chemically adenylated 5’-
phosphate group of the donor oligonucleotide imitates a product of the first step of the ligation reaction
and can be ligated to the second oligonucleotide in the absence of ATP. In the following scheme, a 5’-
App headpiece is ligated to the 3’-OH group of a 5’-phosphorylated oligonucleotide tag (labeled “Tag
A”). Due to the presence of the adenylated 5’-terminus of the oligonucleotide, ligation can occur in the
absence of ATP. Under these conditions, the 5’-phosphate group of Tag A does not serve as a ligation
donor. Building block Tag B can be ligated by providing a nucleotide having a 3’-OH terminus (labeled
“Tag B”) in the presence of ATP, and additional tags (labeled “Tag C”) can be included.
In Figure 3, the 3’-terminus of the headpiece can be blocked with any protecting group (e.g., an
irreversible protecting group, such as ddN, or a reversible protecting group). In the first step, the method
includes ligation of the tag to the 5’-terminus of the headpiece in the absence of ATP, thereby creating a
complex. Successive ligations are performed to the 5’-terminus of the complex in the presence of ATP.
This method can be modified in order to perform successive ligation to the 3’-terminus of a complex. For
example, the method can include the use of a 5’-preadenylated tag and a headpiece having a reactive 3’-
OH terminus. This method may further require blocking the 3’-terminus of the tag to avoid cross-
reactions between tags, such as the method described above and in Figure 2.
The general method provided in Figure 3 can be modified by replacing the primer with a
headpiece. In this case, the headpiece has to be adenylated chemically at the 5’-terminus, and Tag A is
phosphorylated at 5’-terminus. Ligation of this phosphorylated Tag A to the adenylated headpiece occurs
in the same standard conditions, described herein, but omitting ATP. By using this ligation condition, the
ligation of phosphorylated 5’ terminus can be prevented. In the next step, ligation of Tag B requires that
this tag have a free hydroxyl group at 5’-terminus (i.e., non-phosphorylated). Successive ligation
reactions can be performed in the presence of ATP, followed by phosphorylation of the 5’-terminus of the
resulting oligonucleotide if further extension of the tags (e.g., Tag C in Figure 3) is desired.
The methods described herein can include any number of optional steps to diversify the library or
to interrogate the members of the library. For any tagging method described herein (e.g., as in Figures 1-
3), successive “n” number of tags can be added with additional “n” number of ligation, separation, and/or
phosphorylation steps. Exemplary optional steps include restriction of library members using one or
more restriction endonucleases; ligation of one or more adapter sequences to one or both of the library
termini, e.g., such as one or more adapter sequences to provide a priming sequence for amplification and
sequencing or to provide a label, such as biotin, for immobilization of the sequence; reverse-transcription
or transcription, optionally followed by reverse-transcription, of the assembled tags in the complex using
a reverse transcriptase, transcriptase, or another template-dependent polymerase; amplification of the
assembled tags in the complex using, e.g., PCR; generation of clonal isolates of one or more populations
of assembled tags in the complex, e.g., by use of bacterial transformation, emulsion formation, dilution,
surface capture techniques, etc.; amplification of clonal isolates of one or more populations of assembled
tag in the complex, e.g., by using clonal isolates as templates for template-dependent polymerization of
nucleotides; and sequence determination of clonal isolates of one or more populations of assembled tags
in the complex, e.g., by using clonal isolates as templates for template-dependent polymerization with
fluorescently labeled nucleotides. Additional methods for amplifying and sequencing the oligonucleotide
tags are described herein.
These methods can be used to identify and discover any number of chemical entities with a
particular characteristic or function, e.g., in a selection step. The desired characteristic or function may
be used as the basis for partitioning the library into at least two parts with the concomitant enrichment of
at least one of the members or related members in the library with the desired function. In particular
embodiments, the method comprises identifying a small drug-like library member that binds or
inactivates a protein of therapeutic interest. In another embodiment, a sequence of chemical reactions is
designed, and a set of building blocks is chosen so that the reaction of the chosen building blocks under
the defined chemical conditions will generate a combinatorial plurality of molecules (or a library of
molecules), where one or more molecules may have utility as a therapeutic agent for a particular protein.
For example, the chemical reactions and building blocks are chosen to create a library having structural
groups commonly present in kinase inhibitors. In any of these instances, the tags encode the chemical
history of the library member and, in each case, a collection of chemical possibilities may be represented
by any particular tag combination.
In one embodiment, the library of chemical entities, or a portion thereof, is contacted with a
biological target under conditions suitable for at least one member of the library to bind to the target,
followed by removal of library members that do not bind to the target, and analyzing the one or more
oligonucleotide tags associated with them. This method can optionally include amplifying the tags by
methods known in the art. Exemplary biological targets include enzymes (e.g., kinases, phosphatases,
methylases, demethylases, proteases, and DNA repair enzymes), proteins involved in protein:protein
interactions (e.g., ligands for receptors), receptor targets (e.g., GPCRs and RTKs), ion channels, bacteria,
viruses, parasites, DNA, RNA, prions, and carbohydrates.
In another embodiment, the chemical entities that bind to a target are not subjected to
amplification but are analyzed directly. Exemplary methods of analysis include microarray analysis,
including evanescent resonance photonic crystal analysis; bead-based methods for deconvoluting tags
(e.g., by using his-tags); label-free photonic crystal biosensor analysis (e.g., a BIND® Reader from SRU
Biosystems, Inc., Woburn, MA); or hybridization-based approaches (e.g. by using arrays of immobilized
oligonucleotides complementary to sequences present in the library of tags).
In addition, chemically co-reactive pairs (or functional groups) can be readily included in solid-
phase oligonucleotide synthesis schemes and will support the efficient chemical ligation of
oligonucleotides. In addition, the resultant ligated oligonucleotides can act as templates for template-
dependent polymerization with one or more polymerases. Accordingly, any of the binding steps
described herein for tagging encoded libraries can be modified to include one or more of enzymatic
ligation and/or chemical ligation techniques. Exemplary ligation techniques include enzyme ligation,
such as use of one of more RNA ligases and/or DNA ligases; and chemical ligation, such as use of
chemically co-reactive pairs (e.g., a pair including optionally substituted alkynyl and azido functional
groups).
Furthermore, one or more libraries can be combined in a split-and-mix step. In order to permit
mixing of two or more libraries, the library member may contain one or more library-identifying
sequences, such as in a library-identifying tag, in a ligated building block tag, or as part of the headpiece
sequence, as described herein.
Methods having reduced mass
Much of the motivation for single-stranded encoding strategies arises from the reduced mass of a
single-stranded tag when compared to a double-stranded tag. Reduced mass potentially confers several
benefits including increased solubility, decreased cost, increased reactivity, increased target accessibility,
decreased hydrodynamic radius, increased accuracy of analytical assessments, etc. In addition to using a
single-stranded tagging methodology, further reductions in mass can be achieved by including the use of
one or more of the following: one or more tags having a reduced length, constant mass tag sets, an
encoding headpiece, one or more members of a library lacking a primer binding region and/or a constant
region, one or more members of a library having a reduced constant region, or any other methodologies
described herein.
To minimize the mass of the members in the library, the length of one or more building block
tags can be reduced, such as to a length that is as short as possible to encode each split size. In particular,
the tags can be less than 20 nucleotides (e.g., less than 19 nucleotides, less than 18 nucleotides, less than
17 nucleotides, less than 16 nucleotides, less than 15 nucleotides, less than 14 nucleotides, less than 13
nucleotides, less than 12 nucleotides, less than 11 nucleotides, less than 10 nucleotides, less than 9
nucleotides, less than 8 nucleotides, or less than 7 nucleotides). As described below in the Examples,
shorter tags (e.g, about 10 nucleotides or shorter) can be used for tag ligation.
Constant mass strategies can also be used, which could aid in analysis during library synthesis.
In addition, constant mass tag sets could permit the recognition of all single error occurences (e.g., errors
arising from misreading a sequence or from chemical or enzymatic ligation of a tag) and most multiple
error occurrences. The relationship between the length of a constant mass single-stranded tag set and
encoding ability (e.g., minimum lengths to support specific building block split sizes or library identities,
etc.) is outlined below in Table 1. Accordingly, use of constant mass tag sets could be used to provide
beneficial encoding ability, while maintaining error recognition during library formation.
Table 1
To minimize mass in the library, the headpiece can be used not only to link the chemical moiety
and a tag but to also encode for the identity of a particular library or for a particular step. For example,
the headpiece can encode information, e.g., a plurality of headpieces that encode the first split(s) or the
identity of the library, such as by using a particular sequence related to a specific library.
In addition, primer binding (e.g., constant) regions from the library of DNA-encoded chemical
entities can be excluded during the selection step(s). Then, these regions can be added after selection by,
e.g., single-stranded ligation. One exemplary strategy would include providing a chemical entity at the
’-terminus of a encoding oligonucleotide, selecting a particular chemical entity based on any useful
particular characteristic or function, and ligating a tailpiece oligonucleotide to the 3’-terminus of the
encoding oligonucleotide that includes a primer binding sequence and may optionally contain one or
more tags, e.g. a “use” tag, an “origin” tag, etc., as described herein. This primer binding sequence could
then be used to initiate template-dependent polymerization to generate cDNA (or cRNA) that is
complementary to the selected library member. The cDNA or cRNA would then be ligated at its 3’-
terminus to an oligonucleotide that contains a primer binding sequence and, now that the encoding
information is flanked on both sides by primer binding sequences, the oligonucleotide may be sequenced
and/or amplified using established approaches, such as any described herein.
Mass may further be minimized by omitting or reducing the size of one or more constant
sequences that separate encoding tags. Single-stranded ligation requires no complementary relationship
between the ends to be ligated or between these ends and a splint. Therefore, no fixed sequence is
required to support enzymatic ligation. Short fixed regions between tags may be useful for informatic
parsing of tags or other in silico deconvolution processes.
Oligonucleotide tags
The oligonucleotide tags described herein (e.g., a building block tag or a portion of a headpiece)
can be used to encode any useful information, such as a molecule, a portion of a chemical entity, the
addition of a component (e.g., a scaffold or a building block), a headpiece in the library, the identity of
the library, the use of one or more library members (e.g., use of the members in an aliquot of a library),
and/or the origin of a library member (e.g., by use of an origin sequence).
Any sequence in an oligonucleotide can be used to encode any information. Thus, one
oligonucleotide sequence can serve more than one purpose, such as to encode two or more types of
information or to provide a starting oligonucleotide that also encodes for one or more types of
information. For example, the first building block tag can encode for the addition of a first building
block, as well as for the identification of the library. In another example, a headpiece can be used to
provide a starting oligonucleotide that operatively links a chemical entity to a building block tag, where
the headpiece additionally includes a sequence that encodes for the identity of the library (i.e., the library-
identifying sequence). Accordingly, any of the information described herein can be encoded in separate
oligonucleotide tags or can be combined and encoded in the same oligonucleotide sequence (e.g., an
oligonucleotide tag, such as a building block tag, or a headpiece).
A building block sequence encodes for the identity of a building block and/or the type of binding
reaction conducted with a building block. This building block sequence is included in a building block
tag, where the tag can optionally include one or more types of sequence described below (e.g., a library-
identifying sequence, a use sequence, and/or an origin sequence).
A library-identifying sequence encodes for the identity of a particular library. In order to permit
mixing of two or more libraries, a library member may contain one or more library-identifying sequences,
such as in a library-identifying tag (i.e., an oligonucleotide including a library-identifying sequence), in a
ligated building block tag, in a part of the headpiece sequence, or in a tailpiece sequence. These library-
identifying sequences can be used to deduce encoding relationships, where the sequence of the tag is
translated and correlated with chemical (synthesis) history information. Accordingly, these library-
identifying sequences permit the mixing of two or more libraries together for selection, amplification,
purification, sequencing, etc.
A use sequence encodes the history (i.e., use) of one or more library members in an individual
aliquot of a library. For example, separate aliquots may be treated with different reaction conditions,
building blocks, and/or selection steps. In particular, this sequence may be used to identify such aliquots
and deduce their history (use) and thereby permit the mixing together of aliquots of the same library with
different histories (uses) (e.g., distinct selection experiments) for the purposes of the mixing together of
samples together for selection, amplification, purification, sequencing, etc. These use sequences can be
included in a headpiece, a tailpiece, a building block tag, a use tag (i.e., an oligonucleotide including a
use sequence), or any other tag described herein (e.g., a library-identifying tag or an origin tag).
An origin sequence is a degenerate (random) oligonucleotide sequence of any useful length (e.g.,
about six oligonucleotides) that encodes for the origin of the library member. This sequence serves to
stochastically subdivide library members that are otherwise identical in all respects into entities
distinguishable by sequence information, such that observations of amplification products derived from
unique progenitor templates (e.g., selected library members) can be distinguished from observations of
multiple amplification products derived from the same progenitor template (e.g., a selected library
member). For example, after library formation and prior to the selection step, each library member can
include a different origin sequence, such as in an origin tag. After selection, selected library members
can be amplified to produce amplification products, and the portion of the library member expected to
include the origin sequence (e.g., in the origin tag) can be observed and compared with the origin
sequence in each of the other library members. As the origin sequences are degenerate, each
amplification product of each library member should have a different origin sequence. However, an
observation of the same origin sequence in the amplification product could indicate a source of error,
such as an amplification error or a cyclization error in the sequence that produces repeated sequences, and
the starting point or source of these errors can be traced by observing the origin sequence at each step
(e.g., at each selection step or amplification step) of using the library. These origin sequences can be
included in a headpiece, a tailpiece, a building block tag, an origin tag (i.e., an oligonucleotide including
an origin sequence), or any other tag described herein (e.g., a library-identifying tag or a use tag).
Any of the types of sequences described herein can be included in the headpiece. For example,
the headpiece can include one or more of a building block sequence, a library-identifying sequence, a use
sequence, or an origin sequence.
Any of these sequences described herein can be included in a tailpiece. For example, the
tailpiece can include one or more of a library-identifying sequence, a use sequence, or an origin sequence.
These sequences can include any modification described herein for oligonucleotides, such as one
or more modifications that promote solubility in organic solvents (e.g., any described herein, such as for
the headpiece), that provide an analog of the natural phosphodiester linkage (e.g., a phosphorothioate
analog), or that provide one or more non-natural oligonucleotides (e.g., 2’-substituted nucleotides, such as
2’-O-methylated nucleotides and 2’-fluoro nucleotides, or any described herein).
These sequences can include any characteristics described herein for oligonucleotides. For
example, these sequences can be included in tag that is less than 20 nucleotides (e.g., as described
herein). In other examples, the tags including one or more of these sequences have about the same mass
(e.g., each tag has a mass that is about +/- 10% from the average mass between two or more tags); lack a
primer binding (e.g., constant) region; lack a constant region; or have a constant region of reduced length
(e.g., a length less than 30 nucleotides, less than 25 nucleotides, less than 20 nucleotides, less than 19
nucleotides, less than 18 nucleotides, less than 17 nucleotides, less than 16 nucleotides, less than 15
nucleotides, less than 14 nucleotides, less than 13 nucleotides, less than 12 nucleotides, less than 11
nucleotides, less than 10 nucleotides, less than 9 nucleotides, less than 8 nucleotides, or less than 7
nucleotides).
Sequencing strategies for libraries and oligonucleotides of this length may optionally include
concatenation or catenation strategies to increase read fidelity or sequencing depth, respectively. In
particular, the selection of encoded libraries that lack primer binding regions has been described in the
literature for SELEX, such as described in Jarosch et al., Nucleic Acids Res. 34: e86 (2006), which is
incorporated herein by reference. For example, a library member can be modified (e.g., after a selection
step) to include a first adapter sequence on the 5’-terminus of the complex and a second adapter sequence
on the 3’-terminus of the complex, where the first sequence is substantially complementary to the second
sequence and result in forming a duplex. To further improve yield, two fixed dangling nucleotides (e.g.,
CC) are added to the 5’-terminus. In particular embodiments, the first adapter sequence is 5’-
GTGCTGC-3’ (SEQ ID NO: 1), and the second adapter sequence is 5’-GCAGCACCC-3’ (SEQ ID NO:
Headpiece
In the library, the headpiece operatively links each chemical entity to its encoding
oligonucleotide tag. Generally, the headpiece is a starting oligonucleotide having two functional groups
that can be further derivatized, where the first functional group operatively links the chemical entity (or a
component thereof) to the headpiece and the second functional group operatively links one or more tags
to the headpiece. A linker can optionally be used as a spacer between the headpiece and the chemical
entity.
The functional groups of the headpiece can be used to form a covalent bond with a component of
the chemical entity and another covalent bond with a tag. The component can be any part of the small
molecule, such as a scaffold having diversity nodes or a building block. Alternatively, the headpiece can
be derivatized to provide a linker (i.e., a spacer separating the headpiece from the small molecule to be
formed in the library) terminating in a functional group (e.g., a hydroxyl, amine, carboxyl, sulfhydryl,
alkynyl, azido, or phosphate group), which is used to form the covalent linkage with a component of the
chemical entity. The linker can be attached to the 5’-terminus, at one of the internal positions, or to the
3’-terminus of the headpiece. When the linker is attached to one of the internal positions, the linker can
be operatively linked to a derivatized base (e.g., the C5 position of uridine) or placed internally within the
oligonucleotide using standard techniques known in the art. Exemplary linkers are described herein.
The headpiece can have any useful structure. The headpiece can be, e.g., 1 to 100 nucleotides in
length, preferably 5 to 20 nucleotides in length, and most preferably 5 to 15 nucleotides in length. The
headpiece can be single-stranded or double-stranded and can consist of natural or modified nucleotides,
as described herein. Particular exemplary embodiments of the headpiece are described in Figures 4A-4D.
For example, the chemical moiety can be operatively linked to the 3’-terminus (Figure 4A) or 5’-terminus
(Figure 4B) of the headpiece. In particular embodiments, the headpiece includes a hairpin structure
formed by complementary bases within the sequence. For example, the chemical moiety can be
operatively linked to the internal position (Figure 4C), the 3’-terminus (Figure 4D), or the 5’-terminus of
the headpiece.
Generally, the headpiece includes a non-complementary sequence on the 5’- or 3’- terminus that
allows for binding an oligonucleotide tag by polymerization, enzymatic ligation, or chemical reaction. In
Figure 4E, the exemplary headpiece allows for ligation of oligonucleotide tags (labeled 1-4), and the
method includes purification and phosphorylation steps. After the addition of tag 4, an additional adapter
sequence can be added to the 5’-terminus of tag 4. Exemplary adapter sequences include a primer
binding sequence or a sequence having a label (e.g., biotin). In cases where many building blocks and
corresponding tags are used (e.g., 100 tags), a mix-and-split strategy may be employed during the
oligonucleotide synthesis step to create the necessary number of tags. Such mix-and-split strategies for
DNA synthesis are known in the art. The resultant library members can be amplified by PCR following
selection for binding entities versus a target(s) of interest.
The headpiece or the complex can optionally include one or more primer binding sequences. For
example, the headpiece has a sequence in the loop region of the hairpin that serves as a primer binding
region for amplification, where the primer binding region has a higher melting temperature for its
complementary primer (e.g., which can include flanking identifier regions) than for a sequence in the
headpiece. In other embodiments, the complex includes two primer binding sequences (e.g., to enable a
PCR reaction) on either side of one or more tags that encode one or more building blocks. Alternatively,
the headpiece may contain one primer binding sequence on the 5’- or 3’-terminus. In other embodiments,
the headpiece is a hairpin, and the loop region forms a primer binding site or the primer binding site is
introduced through hybridization of an oligonucleotide to the headpiece on the 3’ side of the loop. A
primer oligonucleotide, containing a region homologous to the 3’-terminus of the headpiece and carrying
a primer binding region on its 5’-terminus (e.g., to enable a PCR reaction) may be hybridized to the
headpiece and may contain a tag that encodes a building block or the addition of a building block. The
primer oligonucleotide may contain additional information, such as a region of randomized nucleotides,
e.g., 2 to 16 nucleotides in length, which is included for bioinformatics analysis.
The headpiece can optionally include a hairpin structure, where this structure can be achieved by
any useful method. For example, the headpiece can include complementary bases that form
intermolecular base pairing partners, such as by Watson-Crick DNA base pairing (e.g., adenine-thymine
and guanine-cytosine) and/or by wobble base pairing (e.g., guanine-uracil, inosine-uracil, inosine-
adenine, and inosine-cytosine). In another example, the headpiece can include modified or substituted
nucleotides that can form higher affinity duplex formations compared to unmodified nucleotides, such
modified or substituted nucleotides being known in the art. In yet another example, the headpiece
includes one or more crosslinked bases to form the hairpin structure. For example, bases within a single
strand or bases in different double strands can be crosslinked, e.g., by using psoralen.
The headpiece or complex can optionally include one or more labels that allow for detection. For
example, the headpiece, one or more oligonucleotide tags, and/or one or more primer sequences can
include an isotope, a radioimaging agent, a marker, a tracer, a fluorescent label (e.g., rhodamine or
fluorescein), a chemiluminescent label, a quantum dot, and a reporter molecule (e.g., biotin or a his-tag).
In other embodiments, the headpiece or tag may be modified to support solubility in semi-,
reduced-, or non-aqueous (e.g., organic) conditions. Nucleotide bases of the headpiece or tag can be
rendered more hydrophobic by modifying, for example, the C5 positions of T or C bases with aliphatic
chains without significantly disrupting their ability to hydrogen bond to their complementary bases.
Exemplary modified or substituted nucleotides are 5’-dimethoxytrityl-N4-diisobutylaminomethylidene
(1-propynyl)-2’-deoxycytidine,3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 5’-
dimethoxytrityl(1-propynyl)-2’-deoxyuridine,3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite;
’-dimethoxytritylfluoro-2’-deoxyuridine,3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; and
’-dimethoxytrityl(pyrenyl-ethynyl)-2’-deoxyuridine, or 3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-
phosphoramidite.
In addition, the headpiece oligonucleotide can be interspersed with modifications that promote
solubility in organic solvents. For example, azobenzene phosphoramidite can introduce a hydrophobic
moiety into the headpiece design. Such insertions of hydrophobic amidites into the headpiece can occur
anywhere in the molecule. However, the insertion cannot interfere with subsequent tagging using
additional DNA tags during the library synthesis or ensuing PCR once a selection is complete or
microarray analysis, if used for tag deconvolution. Such additions to the headpiece design described
herein would render the headpiece soluble in, for example, 15%, 25%, 30%, 50%, 75%, 90 %, 95%, 98%,
99%, or 100% organic solvent. Thus, addition of hydrophobic residues into the headpiece design allows
for improved solubility in semi- or non-aqueous (e.g., organic) conditions, while rendering the headpiece
competent for oligonucleotide tagging. Furthermore, DNA tags that are subsequently introduced into the
library can also be modified at the C5 position of T or C bases such that they also render the library more
hydrophobic and soluble in organic solvents for subsequent steps of library synthesis.
In particular embodiments, the headpiece and the first building block tag can be the same entity,
i.e., a plurality of headpiece-tag entities can be constructed that all share common parts (e.g., a primer
binding region) and all differ in another part (e.g., encoding region). These may be utilized in the “split”
step and pooled after the event they are encoding has occurred.
In particular embodiments, the headpiece can encode information, e.g., by including a sequence
that encodes the first split(s) step or a sequence that encodes the identity of the library, such as by using a
particular sequence related to a specific library.
Enzymatic ligation and chemical ligation techniques
Various ligation techniques can be used to add scaffolds, building blocks, linkers, building block
tags, and/or the headpiece to produce a complex. Accordingly, any of the binding steps described herein
can include any useful ligation techniques, such as enzyme ligation and/or chemical ligation. These
binding steps can include the addition of one or more building block tags to the headpiece or complex;
the addition of a linker to the headpiece; and the addition of one or more scaffolds or building blocks to
the headpiece or complex. In particular embodiments, the ligation techniques used for any
oligonucleotide provide a resultant product that can be transcribed and/or reverse transcribed to allow for
decoding of the library or for template-dependent polymerization with one or more DNA or RNA
polymerases.
Generally, enzyme ligation produces an oligonucleotide having a native phosphodiester bond that
can be transcribed and/or reverse transcribed. Exemplary methods of enzyme ligation are provided herein
and include the use of one or more RNA or DNA ligases, such as T4 RNA ligase, T4 DNA ligase,
TM TM TM
CircLigase ssDNA ligase, CircLigase II ssDNA ligase, and ThermoPhage ssDNA ligase
(Prokazyme Ltd., Reykjavik, Iceland).
Chemical ligation can also be used to produce oligonucleotides capable of being transcribed or
reverse transcribed. One benefit of chemical ligation is that solid phase synthesis of such
oligonucleotides can be optimized to support efficient ligation yield. However, the efficacy of a chemical
ligation technique to provide oligonucleotides capable of being transcribed or reverse transcribed may
need to be tested. This efficacy can be tested by any useful method, such as liquid chromatography-mass
spectrometry, RT-PCR analysis, and/or PCR analysis. Examples of these methods are provided in
Example 5.
In particular embodiments, chemical ligation includes the use of one or more chemically co-
reactive pairs to provide a spacer that can be transcribed or reverse transcribed. In particular, reactions
suitable for chemically co-reactive pairs are preferred candidates for the cyclization process (Kolb et al.,
Angew. Chem. Int. Ed., 40:2004-2021 (2001); Van der Eycken et al., QSAR Comb. Sci., 26:1115-1326
(2007)). Exemplary chemically co-reactive pairs are a pair including an optionally substituted alkynyl
group and an optionally substituted azido group to form a triazole spacer via a Huisgen 1,3-dipolar
cycloaddition reaction; an optionally substituted diene having a 4 π electron system (e.g., an optionally
substituted 1,3-unsaturated compound, such as optionally substituted 1,3-butadiene, 1-methoxy
trimethylsilyloxy-1,3-butadiene, cyclopentadiene, cyclohexadiene, or furan) and an optionally substituted
dienophile or an optionally substituted heterodienophile having a 2 π electron system (e.g., an optionally
substituted alkenyl group or an optionally substituted alkynyl group) to form a cycloalkenyl spacer via a
Diels-Alder reaction; a nucleophile (e.g., an optionally substituted amine or an optionally substituted
thiol) with a strained heterocyclyl electrophile (e.g., optionally substituted epoxide, aziridine, aziridinium
ion, or episulfonium ion) to form a heteroalkyl spacer via a ring opening reaction; a phosphorothioate
group with an iodo group, such as in a splinted ligation of an oligonucleotide containing 5’-iodo dT with
a 3’-phosphorothioate oligonucleotide; and an aldehyde group and an amino group, such as a reaction of a
3’-aldehyde-modified oligonucleotide, which can optionally be obtained by oxidizing a commercially
available 3’-glyceryl-modified oligonucleotide, with 5’-amino oligonucleotide (i.e., in a reductive
amination reaction) or a 5’-hydrazido oligonucleotide.
In other embodiments, chemical ligation includes introducing an analog of the phosphodiester
bond, e.g., for post-selection PCR analysis and sequencing. Exemplary analogs of a phosphodiester
include a phosphorothioate linkage (e.g., as introduced by use of a phosphorothioate group and a leaving
group, such as an iodo group), a phosphoramide linkage, or a phosphorodithioate linkage (e.g., as
introduced by use of a phosphorodithioate group and a leaving group, such as an iodo group).
Reaction conditions to promote enzymatic ligation or chemical ligation
Also described herein are one or more reaction conditions that promote enzymatic or chemical
ligation between the headpiece and a tag or between two tags. These reaction conditions include using
modified nucleotides within the tag, as described herein; using donor tags and acceptor tags having
different lengths and varying the concentration of the tags; using different types of ligases, as well as
combinations thereof (e.g., CircLigase DNA ligase and/or T4 RNA ligase), and varying their
concentration; using poly ethylene glycols (PEGs) having different molecular weights and varying their
concentration; use of non-PEG crowding agents (e.g., betaine or bovine serum albumin); varying the
temperature and duration for ligation; varying the concentration of various agents, including ATP,
Co(NH ) Cl , and yeast inorganic pyrophosphate; using enzymatically or chemically phosphorylated
3 6 3
oligonucleotide tags; using 3’-protected tags; and using preadenylated tags. These reaction conditions
also include chemical ligations.
The headpiece and/or tags can include one or more modified or substituted nucleotides. In
preferred embodiments, the headpiece and/or tags include one or more modified or substituted
nucleotides that promote enzymatic ligation, such as 2’-O-methyl nucleotides (e.g., 2’-O-methyl guanine
or 2’-O-methyl uracil), 2’-fluoro nucleotides, or any other modified nucleotides that are utilized as a
substrate for ligation. Alternatively, the headpiece and/or tags are modified to include one or more
chemically reactive groups to support chemical ligation (e.g. an optionally substituted alkynyl group and
an optionally substituted azido group). Optionally, the tag oligonucleotides are functionalized at both
termini with chemically reactive groups, and, optionally, one of these termini is protected, such that the
groups may be addressed independently and side-reactions may be reduced (e.g., reduced polymerization
side-reactions).
Enzymatic ligation can include one or more ligases. Exemplary ligases include CircLigase
ssDNA ligase (EPICENTRE Biotechnologies, Madison, WI), CircLigase II ssDNA ligase (also from
EPICENTRE Biotechnologies), ThermoPhage ssDNA ligase (Prokazyme Ltd., Reykjavik, Iceland), T4
RNA ligase, and T4 DNA ligase. In preferred embodiments, ligation includes the use of an RNA ligase
or a combination of an RNA ligase and a DNA ligase. Ligation can further include one or more soluble
multivalent cations, such as Co(NH ) Cl , in combination with one or more ligases.
3 6 3
Before or after the ligation step, the complex can be purified for three reasons. First, the complex
can be purified to remove unreacted headpiece or tags that may result in cross-reactions and introduce
“noise” into the encoding process. Second, the complex can be purified to remove any reagents or
unreacted starting material that can inhibit or lower the ligation activity of a ligase. For example,
phosphate may result in lowered ligation activity. Third, entities that are introduced into a chemical or
ligation step may need to be removed to enable the subsequent chemical or ligation step. Methods of
purifying the complex are described herein.
Enzymatic and chemical ligation can include poly ethylene glycol having an average molecular
weight of more than 300 Daltons (e.g., more than 600 Daltons, 3,000 Daltons, 4,000 Daltons, or 4,500
Daltons). In particular embodiments, the poly ethylene glycol has an average molecular weight from
about 3,000 Daltons to 9,000 Daltons (e.g., from 3,000 Daltons to 8,000 Daltons, from 3,000 Daltons to
7,000 Daltons, from 3,000 Daltons to 6,000 Daltons, and from 3,000 Daltons to 5,000 Daltons). In
preferred embodiments, the poly ethylene glycol has an average molecular weight from about 3,000
Daltons to about 6,000 Daltons (e.g., from 3,300 Daltons to 4,500 Daltons, from 3,300 Daltons to 5,000
Daltons, from 3,300 Daltons to 5,500 Daltons, from 3,300 Daltons to 6,000 Daltons, from 3,500 Daltons
to 4,500 Daltons, from 3,500 Daltons to 5,000 Daltons, from 3,500 Daltons to 5,500 Daltons, and from
3,500 Daltons to 6,000 Daltons, such as 4,600 Daltons). Poly ethylene glycol can be present in any useful
amount, such as from about 25% (w/v) to about 35% (w/v), such as 30% (w/v).
In a preferred embodiment of this invention, the building block tags are installed by ligation of a
single-stranded oligonucleotide to a single-stranded oligonucleotide using the ligation protocol outlined
below:
Headpiece: 25 μM (5’ terminus: 5’-monophospho/2’-OMe G,
intervening nucleotides: 2’-deoxy, and 3’ terminus: 2’-
blocked/3’-blocked)
Building Block Tag: 25 μM (5’-terminus: 2’-OMe/5’-OH G, intervening
nucleotides: 2’-deoxy, and 3’-terminus: 3’-OH/2’-OMe)
Co(NH ) Cl: 1 mM
3 6 3
PEG 4600: 30% (w/v)
T4 RNA Ligase (Promega): 1.5 units/ μl
Yeast Inorganic Pyrophosphatase: 0.0025 units/ μl
Tris: 50 mM
MgCl: 10 mM
ATP: 1 mM
pH: 7.5
Water: Balance
In further embodiments, the protocol includes incubation at 37°C for 20 hours. For the purposes of actual
library construction, higher concentration of headpiece, tags, and/or ligase may be used, and such
modifications to these concentrations would be apparent to those skilled in the art.
Methods for encoding chemical entities within a library
The methods of the invention can be used to synthesize a library having a diverse number of
chemical entities that are encoded by oligonucleotide tags. Examples of building blocks and encoding
DNA tags are found in U.S. Patent Application Publication No. 2007/0224607, hereby incorporated by
reference.
Each chemical entity is formed from one or more building blocks and optionally a scaffold. The
scaffold serves to provide one or more diversity nodes in a particular geometry (e.g., a triazine to provide
three nodes spatially arranged around a heteroaryl ring or a linear geometry).
The building blocks and their encoding tags can be added directly or indirectly (e.g., via a linker)
to the headpiece to form a complex. When the headpiece includes a linker, the building block or scaffold
is added to the end of the linker. When the linker is absent, the building block can be added directly to
the headpiece or the building block itself can include a linker that reacts with a functional group of the
headpiece. Exemplary linkers and headpieces are described herein.
The scaffold can be added in any useful way. For example, the scaffold can be added to the end
of the linker or the headpiece, and successive building blocks can be added to the available diversity
nodes of the scaffold. In another example, building block A is first added to the linker or the headpiece,
and then the diversity node of scaffold S is reacted with a functional group in building block A .
Oligonucleotide tags encoding a particular scaffold can optionally be added to the headpiece or the
complex. For example, S is added to the complex in n reaction vessels, where n is an integer more than
one, and tag S (i.e., tag S , S , … S , S ) is bound to the functional group of the complex.
n 1 2 n-1 n
Building blocks can be added in multiple, synthetic steps. For example, an aliquot of the
headpiece, optionally having an attached linker, is separated into n reaction vessels, where n is an integer
of two or greater. In the first step, building block A is added to each n reaction vessel (i.e., building
block A , A , … A , A is added to reaction vessel 1, 2, … n-1, n), where n is an integer and each
1 2 n-1 n
building block A is unique. In the second step, scaffold S is added to each reaction vessel to form an A -
S complex. Optionally, scaffold S can be added to each reaction vessel to from an A -S complex, where
n n n
n is an integer of more than two, and each scaffold S can be unique. In the third step, building block B
is to each n reaction vessel containing the A -S complex (i.e., building block B , B , … B , B is added
n 1 2 n-1 n
to reaction vessel 1, 2, … n-1, n containing the A -S, A -S, … A -S, A -S complex), where each
1 2 n-1 n
building block B is unique. In further steps, building block C can be added to each n reaction vessel
containing the B -A -S complex (i.e., building block C , C , … C , C is added to reaction vessel 1, 2, …
n n 1 2 n-1 n
n-1, n containing the B -A -S … B -A -S complex), where each building block C is unique. The
1 1 n n n
resulting library will have n number of complexes having n tags. In this manner, additional synthetic
steps can be used to bind additional building blocks to further diversify the library.
After forming the library, the resultant complexes can optionally be purified and subjected to a
polymerization or ligation reaction using one or more primers. This general strategy can be expanded to
include additional diversity nodes and building blocks (e.g., D, E, F, etc.). For example, the first diversity
node is reacted with building blocks and/or S and encoded by an oligonucleotide tag. Then, additional
building blocks are reacted with the resultant complex, and the subsequent diversity node is derivatized
by additional building blocks, which is encoded by the primer used for the polymerization or ligation
reaction
To form an encoded library, oligonucleotide tags are added to the complex after or before each
synthetic step. For example, before or after the addition of building block A to each reaction vessel, tag
A is bound to the functional group of the headpiece (i.e., tag A , A , … A , A is added to reaction
n 1 2 n-1 n
vessel 1, 2, … n-1, n containing the headpiece). Each tag A has a distinct sequence that correlates with
each unique building block A , and determining the sequence of tag A provides the chemical structure of
building block A . In this manner, additional tags are used to encode for additional building blocks or
additional scaffolds.
Furthermore, the last tag added to the complex can either include a primer sequence or provide a
functional group to allow for binding (e.g., by ligation) of a primer sequence. The primer sequence can
be used for amplifying and/or sequencing the oligonucleotides tags of the complex. Exemplary methods
for amplifying and for sequencing include polymerase chain reaction (PCR), linear chain amplification
(LCR), rolling circle amplification (RCA), or any other method known in the art to amplify or determine
nucleic acid sequences.
Using these methods, large libraries can be formed having a large number of encoded chemical
entities. For example, a headpiece is reacted with a linker and building block An, which includes 1,000
different variants (i.e., n = 1,000). For each building block A , a DNA tag A is ligated or primer
extended to the headpiece. These reactions may be performed in a 1,000-well plate or 10 x 100 well
plates. All reactions may be pooled, optionally purified, and split into a second set of plates. Next, the
same procedure may be performed with building block B , which also include 1,000 different variants. A
DNA tag B may be ligated to the A -headpiece complex, and all reactions may be pooled. The resultant
library includes 1,000 x 1,000 combinations of A x B (i.e., 1,000,000 compounds) tagged by 1,000,000
different combinations of tags. The same approach may be extended to add building blocks C , D , E ,
n n n
etc. The generated library may then be used to identify compounds that bind to the target. The structure
of the chemical entities that bind to the library can optionally be assessed by PCR and sequencing of the
DNA tags to identify the compounds that were enriched.
This method can be modified to avoid tagging after the addition of each building block or to
avoid pooling (or mixing). For example, the method can be modified by adding building block A to n
reaction vessels, where n is an integer of more than one, and adding the identical building block B to
each reaction well. Here, B is identical for each chemical entity, and, therefore, an oligonucleotide tag
encoding this building block is not needed. After adding a building block, the complexes may be pooled
or not pooled. For example, the library is not pooled following the final step of building block addition,
and the pools are screened individually to identify compound(s) that bind to a target. To avoid pooling all
of the reactions after synthesis, a BIND Reader (from SRU Biosystems, Inc.), for example, may be used
to monitor binding on a sensor surface in high throughput format (e.g., 384 well plates and 1,536 well
plates). For example, building block A may be encoded with DNA tag A , and building block B may be
n n n
encoded by its position within the well plate. Candidate compounds can then be identified by using a
binding assay (e.g., using a BIND Biosensor, also available by SRU Biosystems, Inc., or using an
ELISA assay) and by analyzing the A tags by sequencing, microarray analysis and/or restriction digest
analysis. This analysis allows for the identification of combinations of building blocks A and B that
produce the desired molecules.
The method of amplifying can optionally include forming a water-in-oil emulsion to create a
plurality of aqueous microreactors. The reaction conditions (e.g., concentration of complex and size of
microreactors) can be adjusted to provide, on average, a microreactor having at least one member of a
library of compounds. Each microreactor can also contain the target, a single bead capable of binding to
a complex or a portion of the complex (e.g., one or more tags) and/or binding the target, and an
amplification reaction solution having one or more necessary reagents to perform nucleic acid
amplification. After amplifying the tag in the microreactors, the amplified copies of the tag will bind to
the beads in the microreactors, and the coated beads can be identified by any useful method.
Once the building blocks from the first library that bind to the target of interest have been
identified, a second library may be prepared in an iterative fashion. For example, one or two additional
nodes of diversity can be added, and the second library is created and sampled, as described herein. This
process can be repeated as many times as necessary to create molecules with desired molecular and
pharmaceutical properties.
Various ligation techniques can be used to add the scaffold, building blocks, linkers, and building
block tags. Accordingly, any of the binding steps described herein can include any useful ligation
technique or techniques. Exemplary ligation techniques include enzymatic ligation, such as use of one of
more RNA ligases and/or DNA ligases, as described herein; and chemical ligation, such as use of
chemically co-reactive pairs, as described herein.
Scaffold and building blocks
The scaffold S can be a single atom or a molecular scaffold. Exemplary single atom scaffolds
include a carbon atom, a boron atom, a nitrogen atom, or a phosphorus atom, etc. Exemplary polyatomic
scaffolds include a cycloalkyl group, a cycloalkenyl group, a heterocycloalkyl group, a
heterocycloalkenyl group, an aryl group, or a heteroaryl group. Particular embodiments of a heteroaryl
scaffold include a triazine, such as 1,3,5-triazine, 1,2,3-triazine, or 1,2,4-triazine; a pyrimidine; a
pyrazine; a pyridazine; a furan; a pyrrole; a pyrrolline; a pyrrolidine; an oxazole; a pyrazole; an isoxazole;
a pyran; a pyridine; an indole; an indazole; or a purine.
The scaffold S can be operatively linked to the tag by any useful method. In one example, S is a
triazine that is linked directly to the headpiece. To obtain this exemplary scaffold, trichlorotriazine (i.e., a
chlorinated precursor of triazine having three chlorines) is reacted with a nucleophilic group of the
headpiece. Using this method, S has three positions having chlorine that are available for substitution,
where two positions are available diversity nodes and one position is attached to the headpiece. Next,
building block A is added to a diversity node of the scaffold, and tag A encoding for building block A
n n n
(“tag A ”) is ligated to the headpiece, where these two steps can be performed in any order. Then,
building block B is added to the remaining diversity node, and tag B encoding for building block B is
n n n
ligated to the end of tag A . In another example, S is a triazine that is operatively linked to the linker of a
tag, where trichlorotriazine is reacted with a nucleophilic group (e.g., an amino group) of a PEG,
aliphatic, or aromatic linker of a tag. Building blocks and associated tags can be added, as described
above.
In yet another example, S is a triazine that is operatively linked to building block A . To obtain
this scaffold, building block A having two diversity nodes (e.g., an electrophilic group and a nucleophilic
group, such as an Fmoc-amino acid) is reacted with the nucleophilic group of a linker (e.g., the terminal
group of a PEG, aliphatic, or aromatic linker, which is attached to a headpiece). Then, trichlorotriazine is
reacted with a nucleophilic group of building block A . Using this method, all three chlorine positions of
S are used as diversity nodes for building blocks. As described herein, additional building blocks and
tags can be added, and additional scaffolds S can be added.
Exemplary building block A ’s include, e.g., amino acids (e.g., alpha-, beta-, gamma-, delta-, and
epsilon- amino acids, as well as derivatives of natural and unnatural amino acids), chemically co-reactive
reactants (e.g., azide or alkyne chains) with an amine, or a thiol reactant, or combinations thereof. The
choice of building block A depends on, for example, the nature of the reactive group used in the linker,
the nature of a scaffold moiety, and the solvent used for the chemical synthesis.
Exemplary building block Bn’s and Cn’s include any useful structural unit of a chemical entity,
such as optionally substituted aromatic groups (e.g., optionally substituted phenyl or benzyl), optionally
substituted heterocyclyl groups (e.g., optionally substituted quinolinyl, isoquinolinyl, indolyl, isoindolyl,
azaindolyl, benzimidazolyl, azabenzimidazolyl, benzisoxazolyl, pyridinyl, piperidyl, or pyrrolidinyl),
optionally substituted alkyl groups (e.g., optionally substituted linear or branched C alkyl groups or
optionally substituted C aminoalkyl groups), or optionally substituted carbocyclyl groups (e.g.,
optionally substituted cyclopropyl, cyclohexyl, or cyclohexenyl). Particularly useful building block B ’s
and C ’s include those with one or more reactive groups, such as an optionally substituted group (e.g.,
any described herein) having one or optional substituents that are reactive groups or can be chemically
modified to form reactive groups. Exemplary reactive groups include one or more of amine (-NR , where
each R is, independently, H or an optionally substituted C alkyl), hydroxy, alkoxy (-OR, where R is an
optionally substituted C alkyl, such as methoxy), carboxy (-COOH), amide, or chemically co-reactive
substituents. A restriction site may be introduced, for example, in tag B or C , where a complex can be
identified by performing PCR and restriction digest with one of the corresponding restriction enzymes.
Linkers
The bifunctional linker between the headpiece and the chemical entity can be varied to provide an
appropriate spacer and/or to increase the solubility of the headpiece in organic solvent. A wide variety of
linkers are commercially available that can couple the headpiece with the small molecule library. The
linker typically consists of linear or branched chains and may include a C alkyl, a heteroalkyl of 1 to
1-10
atoms, a C alkenyl, a C alkynyl, C aryl, a cyclic or polycyclic system of 3 to 20 atoms, a
2-10 2-10 5-10
phosphodiester, a peptide, an oligosaccharide, an oligonucleotide, an oligomer, a polymer, or a poly alkyl
glycol (e.g., a poly ethylene glycol, such as –(CH CH O) CH CH -, where n is an integer from 1 to 50),
2 2 n 2 2
or combinations thereof.
The bifunctional linker may provide an appropriate spacer between the headpiece and a chemical
entity of the library. In certain embodiments, the bifunctional linker includes three parts. Part 1 may be a
reactive group, which forms a covalent bond with DNA, such as, e.g., a carboxylic acid, preferably
activated by a N-hydroxy succinimide (NHS) ester to react with an amino group on the DNA (e.g.,
amino-modified dT), an amidite to modify the 5’ or 3’-terminus of a single-stranded headpiece (achieved
by means of standard oligonucleotide chemistry), chemically co-reactive pairs (e.g., azido-alkyne
cycloaddition in the presence of Cu(I) catalyst, or any described herein), or thiol reactive groups. Part 2
may also be a reactive group, which forms a covalent bond with the chemical entity, either building block
A or a scaffold. Such a reactive group could be, e.g., an amine, a thiol, an azide, or an alkyne. Part 3
may be a chemically inert spacer of variable length, introduced between Part 1 and 2. Such a spacer can
be a chain of ethylene glycol units (e.g., PEGs of different lengths), an alkane, an alkene, a polyene chain,
or a peptide chain. The linker can contain branches or inserts with hydrophobic moieties (such as, e.g.,
benzene rings) to improve solubility of the headpiece in organic solvents, as well as fluorescent moieties
(e.g. fluorescein or Cy-3) used for library detection purposes. Hydrophobic residues in the headpiece
design may be varied with the linker design to facilitate library synthesis in organic solvents. For
example, the headpiece and linker combination is designed to have appropriate residues wherein the
octanol:water coefficient (P ) is from, e.g., 1.0 to 2.5.
Linkers can be empirically selected for a given small molecule library design, such that the
library can be synthesized in organic solvent, for example, in 15%, 25%, 30%, 50%, 75%, 90%, 95%,
98%, 99%, or 100% organic solvent. The linker can be varied using model reactions prior to library
synthesis to select the appropriate chain length that solubilizes the headpiece in an organic solvent.
Exemplary linkers include those having increased alkyl chain length, increased poly ethylene glycol units,
branched species with positive charges (to neutralize the negative phosphate charges on the headpiece), or
increased amounts of hydrophobicity (for example, addition of benzene ring structures).
Examples of commercially available linkers include amino-carboxylic linkers, such as those
being peptides (e.g., Z-Gly-Gly-Gly-Osu (N-alpha-benzyloxycarbonyl-(Glycine) -N-succinimidyl ester)
or Z-Gly-Gly-Gly-Gly-Gly-Gly-Osu (N-alpha-benzyloxycarbonyl-(Glycine) -N-succinimidyl ester, SEQ
ID NO: 3)), PEG (e.g., Fmoc-aminoPEG2000-NHS or amino-PEG (12-24)-NHS), or alkane acid chains
(e.g., Boc- ε-aminocaproic acid-Osu); chemically co-reactive pair linkers, such as those chemically co-
reactive pairs described herein in combination with a peptide moiety (e.g., azidohomoalanine-Gly-Gly-
Gly-OSu (SEQ ID NO: 4) or propargylglycine-Gly-Gly-Gly-OSu (SEQ ID NO: 5)), PEG (e.g., azido-
PEG-NHS), or an alkane acid chain moiety (e.g., 5-azidopentanoic acid, (S)(azidomethyl)Boc-
pyrrolidine, 4-azidoaniline, or 4-azido-butanoic acid N-hydroxysuccinimide ester); thiol-reactive
linkers, such as those being PEG (e.g., SM(PEG)n NHS-PEG-maleimide), alkane chains (e.g., 3-(pyridin-
2-yldisulfanyl)-propionic acid-Osu or sulfosuccinimidyl 6-(3’-[2-pyridyldithio]-
propionamido)hexanoate)); and amidites for oligonucleotide synthesis, such as amino modifiers (e.g., 6-
(trifluoroacetylamino)-hexyl-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite), thiol modifiers (e.g., S-
tritylmercaptohexyl[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, or chemically co-reactive
pair modifiers (e.g., 6-hexynyl-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite, 3-
dimethoxytrityloxy(3-(3-propargyloxypropanamido)propanamido)propylO-succinoyl, long chain
alkylamino CPG, or 4-azido-butanoic acid N-hydroxysuccinimide ester)). Additional linkers are
known in the art, and those that can be used during library synthesis include, but are not limited to, 5’-O-
dimethoxytrityl-1’,2’-dideoxyribose-3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 9-O-
dimethoxytrityl-triethylene glycol,1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 3-(4,4’-
dimethoxytrityloxy)propyl[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; and 18-O-
dimethoxytrityl hexaethyleneglycol,1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite. Any of the
linkers herein can be added in tandem to one another in different combinations to generate linkers of
different desired lengths.
Linkers may also be branched, where branched linkers are well known in the art and examples
can consist of symmetric or asymmetric doublers or a symmetric trebler. See, for example, Newcome et
al., Dendritic Molecules: Concepts, Synthesis, Perspectives, VCH Publishers (1996); Boussif et al., Proc.
Natl. Acad. Sci. USA 92:7297-7301 (1995); and Jansen et al., Science 266:1226 (1994).
Example 1
General strategy to improve single-stranded ligation of DNA tags
Various reaction conditions were explored to improve single-stranded ligation of tags to form an
encoded library. These reaction conditions included using modified nucleotides within the tag (e.g., use
of one or more nucleotides having a 2’-OMe group to form a MNA/DNA tag, where “MNA” refers to an
oligonucleotide having at least one 2’-O-methyl nucleotide); using donor tags and acceptor tags having
different lengths and varying the concentration of the tags; using different types of ligases, as well as
combinations thereof (e.g., CircLigase ssDNA ligase and/or T4 RNA ligase), and varying their
concentration; purifying the complex by removing unreacted starting materials; using poly ethylene
glycols (PEGs) having different molecular weights and varying their concentration; varying the
temperature and duration for reaction, such as ligation; varying the concentration of various agents,
including ATP, Co(NH ) Cl , and yeast inorganic pyrophosphate; using enzymatically or chemically
3 6 3
phosphorylated oligonucleotide tags; using 3’-protected tags; and using 5’-chemically adenylated tags.
After a thorough analysis of different conditions, optimal combinations of parameters that
provided up to 90% ligation efficiency (e.g., Figure 5C), as determined by the fraction of ligated final
product to un-ligated starting reactant (“fraction ligated”), were found. A scheme of the ligation reaction
using ligase is shown in Figure 5A, and a typical denaturing polyacrylamide gel electrophoresis is shown
in Figure 5B. The donor oligonucleotide was labeled at the 3’-terminus and could be detected on a gel by
scanning at 450 nm excitation on a Storm 800 PhosphorImager. The gel depicts an unligated donor (or
starting material) and the ligated product. In particular, the adenylated donor can be resolved and
distinguished from the starting material on this gel.
Table 2 provides ligation efficiencies measured as a function of the composition of the
oligonucleotide (i.e., oligonucleotides with all DNA nucleotides versus oligonucleotides with at least one
2’-O-methyl nucleotide, labeled “MNA”) and the type of ligase (i.e., RNA ligase versus ssDNA ligase).
These ligation experiments included the following tags: an all-DNA donor having the sequence of 5’-P-
GCT GTG CAG GTA GAG TGCFAM-3’ (SEQ ID NO: 6); a 5’-MNA-DNA donor having the
sequence of 5’-P-mGCT GTG CAG GTA GAG TGCFAM-3’ (SEQ ID NO: 7); an all-MNA donor
having the sequence of 5’-P-mGmUmG mCmAmG mGmUmA mGmAmG mUmGmCFAM-3’ (SEQ
ID NO: 8); a DNA-3’MNA acceptor having the sequence of 5’-HO-TAC GTA TAC GAC TGmG-OH-3’
(SEQ ID NO: 9); an all-DNA acceptor having the sequence of 5’-HO-GCA GAC TAC GTA TAC GAC
TGG-OH-3’ (SEQ ID NO: 10); and an all-MNA acceptor having the sequence of 5’-HO-mUmAmC
mGmUmA mUmAmC mGmAmC mUmGmG-OH-3’ (SEQ ID NO: 11), where “m” indicates a 2’-OMe
base, “P” indicates a phosphorylated nucleotide, and “FAM” indicates fluorescein.
Ligation efficiencies were calculated from gel densitometry data as the ratio between the intensity
from the ligation product and the sum of the intensity from the ligation product and the unligated starting
material. The reaction conditions for T4 RNA ligase included the following: 5 μM each of donor and
acceptor oligonucleotides (15-18 nucleotides (nts) long) in a buffer solution containing 50 mM Tris HCl,
mM MgCl2, 1 mM hexamine cobalt chloride, 1 mM ATP, 25% PEG4600, and 5 units of T4 RNA
ligase (NEB- new units) at pH 7.5. The reactions were incubated at 37°C for 16 hours. The reaction
conditions for CircLigase™ included the following: 5 μM each of donor and acceptor oligonucleotides
(length 15 or 18 nts) incubated in a buffer containing 50 mM MOPS (pH 7.5), 10 mM KCl, 5 mM MgCl ,
1 mM DTT, 0.05 mM ATP, 2.5 mM MnCl , and 25% (w/v) PEG 8000 with 20 units of CircLigase™
(Epicentre) at 50°C for 16 hours. The reactions were resolved on 8M urea/15% PAAG, followed by
densitometry using excitation at 450 nm.
Table 2
Donor Acceptor T4 RNA ligase CircLigase™
All-DNA All-DNA 9 % 89%
All-DNA All-MNA 14% 68%
All-DNA DNA-3’MNA 46% 85%
All-MNA All-DNA 11% 84%
All-MNA All-MNA 20% 29%
All-MNA DNA-3’MNA 32% 73%
’-MNA-DNA All-DNA 29% 90%
’-MNA-DNA All-MNA 16 % 46%
’-MNA-DNA DNA-3’MNA 69% 81%
Generally, CircLigase™ produced higher ligation yields than T4 RNA ligase (Table 2). When
both donor and acceptor were DNA/MNA hybrid oligonucleotides, efficient ligation was achieved with
T4 RNA ligase.
Figure 5C shows high yield ligation achieved for T4 RNA ligase at high enzyme and
oligonucleotide concentrations. The reaction conditions included following: 250 μM each of donor and
acceptor oligonucleotides in a buffer containing 50 mM Tris HCl, 10 mM MgCl , 1 mM hexamine cobalt
chloride, 2.5 mM ATP, 30% (w/v) PEG4600, pH 7.5, different amounts of T4 RNA ligase at 40 units/ μL
(NEB- new units), and 0.1 unit of yeast inorganic pyrophosphatase. The reactions were incubated at
37°C for 5 and 20 hours and resolved on 8M urea/15% PAAG, followed by densitometry using excitation
at 450 nm.
Overall, these data suggest that enzymatic ligation can be optimized by including one or more
modified 2’-nucleotides and/or by using an RNA or DNA ligase. Further details for several other tested
conditions, such as PEG or tag length, that can contribute to ligation efficiency are discussed below.
Example 2
Effect of PEG on single-stranded ligation
To determine the effect of PEG molecular weight (MW) on ligation, single-stranded tags were
ligated with 25% (w/v) of PEG having a MW from 300 to 20,000 Daltons. As shown in Figure 6A, 80%
or greater ligation was observed for PEG having a MW of 3,350, 4,000, 6,000, 8,000, and 20,000. These
ligation experiments included the following tags: a 15mer donor having the sequence of 5’-P-mGTG
CAG GTA GAG TGCFAM-3’ (SEQ ID NO: 12) and a 15mer acceptor having the sequence of 5’-HO-
mUAC GTA TAC GAC TGmG-OH-3’ (SEQ ID NO: 13). These oligonucleotide tags were DNA
sequences with one or two terminal 2’O-methyl (2’-OMe) RNA bases (e.g., 2’-OMe-U (mU) or 2’-OMe-
G (mG)).
Experiments were also conducted to determine the effect of PEG concentration. Single-stranded
tags were ligated with various concentration of PEG having a MW of 4,600 Daltons (PEG4600). As
shown in Figure 6B, 70% or greater ligation, on average, was observed for 25% (w/v) to 35% (w/v)
PEG4600.
Example 3
Effect of tag length on single-stranded ligation
To determine the effect of tag length on ligation, acceptor and donor tags of various lengths were
constructed. For CircLigase™ experiments, a 15mer donor having the sequence 5’-P-mGTG CAG GTA
GAG TGCFAM-3’ (SEQ ID NO: 12) was used and paired with 10, 12, 14, 16, and 18mer DNA
acceptor oligonucleotides. For T4 RNA ligase experiments, the tags included one or more 2’-OMe-bases
(designated as being MNA/DNA tags). Table 3 provides the sequence for the three donor tags (15mer,
8mer, and 5mer) and the three acceptor tags (15mer, 8mer, and 5mer).
Table 3
Oligonucleotide tag Sequence*
15mer donor 5’-P-mGTG CAG GTA GAG TGCFAM-3’ (SEQ ID NO: 12)
15mer acceptor 5’-HO-mUAC GTA TAC GAC TGmG-OH-3’ (SEQ ID NO: 13)
8mer donor 5’-P-mGT GAG TGCFAM-3’ (SEQ ID NO: 14)
8mer acceptor 5’-HO-C A GAC TGmG-OH-3’ (SEQ ID NO: 15)
5mer donor 5’-P-mGT GACFAM-3’ (SEQ ID NO: 16)
5mer acceptor 5’-HO-mAC TGmG-OH-3’ (SEQ ID NO: 17)
* “m” indicates a 2’-OMe base, “P” indicates a phosphorylated nucleotide, and “FAM” indicates
fluorescein.
The extent of ligation was analyzed by densitometry of electrophoretic gels (Figures 7A-7B).
The results of the CircLigase™ reactions indicate a strong dependence of ligation yield on the length of
the acceptor oligonucleotide (Figure 7A). The highest ligation yield was observed with an 18mer
acceptor (62%), while ligation yield with a 10mer acceptor was lower than 10%. The results of the T4
RNA ligase reactions indicate that the combination of an 8mer acceptor with an 8mer donor provided the
highest yield and that combinations having a 15mer donor with any of the tested acceptors provided
yields greater than 75% (Figure 7B). If a library includes shorter tags (i.e., about 10mer or shorter), then
T4 RNA ligase may be preferred for tag ligation. In other cases, ligation can be further optimized by
using CircLigase™ or a combination of T4 RNA ligase and CircLigase .
Example 4
Effect of purification on single-stranded ligation
To determine the effect of purification on ligation, single-stranded tags were ligated to imitate the
library synthetic process. For these experiments, the tags included 15mer donor and 15mer acceptor tags,
as provided above in Table 3. The chemical entity was bound to the 3’-terminus of the library, where the
chemical entity was fluorescein in this example to aid in visualization. As shown in Figure 9 (right),
successive tags were ligated to the 5’-OH group of the complex after phosphorylation by T4 PNK.
Experiments were also conducted by purifying the ligated product (i.e., the complex) prior to the
PNK reaction, where particular agents useful in the ligation reaction (e.g., phosphate, cobalt, and/or
unreacted tags) can inhibit the phosphorylation reaction with PNK or reduce ligation yield. As shown in
Figure 9 (left), purifying the complex (i.e., minimal precipitation) prior to the PNK reaction increased
ligation (see data marked with *, indicating purification). Figures 8A-8B show LC-MS spectra for a
15mer MNA/DNA tag before and after phosphorylation. The presence or absence of DTT had no effect
on phosphorylation.
Example 5
Chemically co-reactive pair ligation and reverse transcription of junctions
The methods described herein can further include chemically co-reactive pair ligation techniques,
as well as enzyme ligation techniques. Accordingly, as an example of chemical ligation, an exemplary
chemically co-reactive pair (i.e., an alkyne and an azido pair in a cycloaddition reaction) in two variants:
a short chemically co-reactive pair and a long chemically co-reactive pair, was used.
Materials
In a first variant, a short chemically co-reactive pair (Figure 10A) was used. The pair included (i)
an oligonucleotide having the sequence 5’-GCG TGA ACA TGC ATC TCC CGT ATG CGT ACA GTC
CAT T/propargylG/-3’ (“5end3propargyl,” SEQ ID NO: 18) and (ii) an oligonucleotide having the
sequence 5’-/azidoT/ATA GCG CGA TAT ACA CAC TGG CGA GCT TGC GTA CTG-3’
(“3end5azido,” SEQ ID NO: 19). This pair of oligonucleotides was prepared by TriLink
BioTechnologies, Inc. (San Diego, CA). These oligonucleotides were designed to produce a short spacer
between two oligonucleotides upon ligation, where the linker would be 5 atoms long (counting from the
C3’-position of the 5end3propargyl oligonucleotide to the C5’-position of the 3end5azido
oligonucleotide). In addition, the 5’-azido oligonucleotide (3end5azido) was prepared by converting the
iodo group in the corresponding 5’-iodo oligonucleotide into an azido group.
In a second variant, a long chemically co-reactive pair (Figure 10B) was used. The pair included
(i) an oligonucleotide having the sequence 5’-GCG TGA ACA TGC ATC TCC CGT ATG CGT ACA
GTC CAT TG/spacer7-azide/-3’ (“5end3azide,” SEQ ID NO: 20) and (ii) an oligonucleotide having the
sequence 5’-/hexynyl/TA GCG CGA TAT ACA CAC TGG CGA GCT TGC GTA CTG-3’
(“3end5hexynyl,” SEQ ID NO: 21). This pair of oligonucleotides was prepared by Integrated DNA
Technologies, Inc. (IDT DNA, San Diego, CA, and Coralville, IA). The 5end3azide oligonucleotide was
prepared by reacting an azidobutyrate N-hydroxysuccinimide ester with a 3’-amino-modifier C7 (2-
dimethoxytrityl oxymethylfluorenylmethoxycarbonylamino-hexanesuccinoyl-long chain
alkylamino), which was introduced during oligonucleotide column synthesis. This pair was designed to
produce a 24 atom long spacer between the oligonucleotides (counting from the C3’-position of the
5end3azide oligonucleotide to the C5’-position of the 3end5hexynyl oligonucleotide).
For reverse transcription (as shown by the schematic in Figure 11A), the primers and templates
included the following: a reverse transcription primer having the sequence of 5’-/Cy5/ CAG TAC GCA
AGC TCG-3’ (“Cy5s_primer15,” SEQ ID NO: 22); a control template having the sequence of 5’-GCG
TGA ACA TGC ATC TCC CGT ATG CGT ACA GTC CAT TGT ATA GCG CGA TAT ACA CAC
TGG CGA GCT TGC GTA CTG-3’ (“templ75,” SEQ ID NO: 23); a 5’-PCR primer having the sequence
of 5’-GCG TGA ACA TGC ATC TCC-3’ (SEQ ID NO: 24); and a 3’-PCR primer having the sequence
of 5’-CAG TAC GCA AGC TCG CC-3’ (SEQ ID NO: 25), where these sequences were obtained from
IDT DNA. A Cy5-labeled DNA primer was used for the experiments to enable separate detection of the
reverse transcription products by LC.
Experimental Conditions
For the chemically co-reactive pair ligations, 1 mM solutions of chemically co-reactive pairs,
such as 5end3propargyl+3end5azido (short) or 5end3azide+3end5hexynyl (long), were incubated for 12
hours in the presence of 100 equivalents of TBTA ligand (tris-[(1-benzyl-1H-1,2,3-triazol
yl)methyl]amine) and 50 equivalents of CuBr in a water/dimethyl acetate mixture. Following the
reaction, an excess of EDTA was added, and the reaction mixtures were desalted using Zeba Spin
Desalting Columns (Invitrogen Corp., Carlsbad, CA) and then ethanol precipitated. For the reverse
transcription reactions, the templates were purified on a 15% polyacrylamide gel containing 8M urea.
Liquid chromatography-mass spectrometry (LC-MS) was performed on a Thermo Scientific LCQ
Fleet using an ACE 3 C18-300 (50 x 2.1 mm) column and a 5 minute gradient of 5-35% of buffer B using
buffer A (1% hexafluoroisopropanol (HFIP), 0.1% di-isopropylethyl amine (DIEA), 10 μM EDTA in
water) and buffer B (0.075% HFIP, 0.0375% DIEA, 10 μM EDTA, 65% acetonitrile/35% water). LC
was monitored at 260 nm and 650 nm. MS was detected in the negative mode, and mass peak
deconvolution was performed using ProMass software.
Reverse transcription reactions were performed using ThermoScript RT (Invitrogen Corp.),
according to the manufacturer’s protocol, at 50°C for 1-2 hours. The results were analyzed by LC-MS
and by PCR. PCR was performed using Platinum® SuperMix and resolved on 4% agarose E-Gels (both
from Invitrogen Corp.). Eleven and eighteen cycles of PCR were performed with or without a preceding
RT reaction. The 75mer template was not reverse transcribed and used directly for the PCR
amplification.
Results and discussion
In both the ligations forming a short spacer and a long spacer, reaction yields were high, close to
quantitative, as analyzed by LC-MS. Accordingly, chemical ligation provides a high yield technique to
bind or operatively associate a headpiece to one or more building block tags.
For a viable chemical ligation strategy to produce DNA-encoded libraries, the resultant complex
should be capable of undergoing PCR or RT-PCR for further sequencing applications. While PCR and
RT-PCR may not be an issue with enzymatically ligated tags, such as described above, unnatural
chemical linkers may be difficult to process by RNA or DNA polymerases. The data provided in Figures.
11B-11E suggest that oligonucleotides having a spacer of particular lengths can be transcribed and/or
reverse transcribed.
In the case of a chemically co-reactive pair linker resulting in a triazole-linked oligonucleotide, a
dependence on the length of the linker was observed. For the short chemically co-reactive pair, the
resultant template was reverse transcribed and analyzed by LC-MS. LC analysis revealed three major
absorption peaks at 2.79 min., 3.47 min., and 3.62 min. for 260 nm, where the peaks at 3.47 min. and 3.62
min. also provided absorption peaks at 650 nm. MS analysis of the peak at 3.47 min. showed only the
presence of the template 23097.3 (calc’d 23098.8), and the peak at 3.62 min. contained a template
(23098.0) and a fully extended primer (23670.8, calc’d: 23671.6) at an approximately 1.7:1 ratio,
suggesting a 50-60% yield for this RT reaction (Figure 11C). For comparison, reverse transcription (RT)
of the control having an all-DNA template produced the extended primer (peak 23068.9) in an amount
roughly equivalent to the template (23078.7), suggesting close to a 100% yield (Figure 11B).
For the long chemically co-reactive pair, LC of the RT reaction showed two absorption peaks at
2.77 min and 3.43 min for 260 nm, where the peak at 3.43 min also provided absorption peaks at 650 nm,
i.e., contained a Cy5 labeled material, which is the expected RT product. MS analysis of the peak at 3.43
min. revealed the template (observed 23526.6, calc’d: 23534.1), as well as the Cy5 primer extended to the
linker (11569.1). No full length product was observed by LC-MS, indicating that the RT reaction did not
occur in a measureable amount (Figure 11D).
RT-PCR was performed with the templates described above and revealed that only the short
linker yielded reverse transcription product, albeit at 5-10 lower efficiency (Figure 11E). Efficiency of
the RT was estimated to be about 2-fold lower than the template (templ75). For example, the PCR
product of the short ligated template around 2-fold lower after RT and around 5-10 times lower without
RT, as compared to the PCR product of the all-DNA template 75 (templ75). Accordingly, these data
provide support for the use of chemical ligation to produce a complex that can be reverse transcribed
and/or transcribed, and chemically ligated headpieces and/or tags can be used in any of the binding steps
described herein to produce encoded libraries.
Example 6
Ligation of 3’-phosphorothioate oligonucleotides with 5’-iodo oligonucleotides
To determine the flexibility of the methods described herein, the ligation efficiency of
oligonucleotides having other modifications were determined. In particular, analogs of the natural
phosphodiester linkage (e.g., a phosphorothioate analog) could provide an alternative moiety for post-
selection PCR analysis and sequencing.
The following oligonucleotides were synthesized by TriLink BioTechnologies, Inc. (San Diego,
CA): (i) 5’-/Cy5/ CGA TAT ACA CAC TGG CGA GCT/thiophosphate/-3’ (“CCy5,” SEQ ID NO: 26),
(ii) 5’-/IododT/ GC GTA CTG AGC/6-FAM/-3’ (“CFL,” SEQ ID NO: 27), as shown in Figure 12A, and
(iii) a splint oligonucleotide having the sequence of CAG TAC GCA AGC TCG CC (“spl,” SEQ ID NO:
28). Ligation reactions were performed with 100 μM of each reactant oligonucleotide in a buffer
containing 50mM Tris HCl (pH 7.0), 100 mM NaCl, and 10 mM MgCl (“ligation buffer”) at room
temperature. The ligation reactions were supplemented by either of the following: 100 μM of the splint
oligonucleotide, 10 mM Co(NH ) Cl , 40% (w/v) of PEG4000, or 80% (w/v) of PEG300. The reaction
3 6 3
was allowed to progress for up to 48 hours. Ligation products were analyzed by LC-MS using detection
at 260 nm, 495 nm, and 650 nm, as well as by an 8M urea/ 15% polyacrylamide gel (PAAG) that was
further scanned at 450 and 635 nm excitation on a Storm 800 PhosphorImager.
In the absence of the splint oligonucleotide, no ligation was observed (Figure 12B, lanes labeled
“-spl”). In the presence of the splint oligonucleotide, ligation occurred and reached around 60% of
fraction ligated after 48 hours (Figures 12B-12C). LC-MS revealed several peaks in the chromatogram,
with a peak at 3.00 min absorbing at 260 nm, 495 nm, and 650 nm. MS of this peak showed mostly the
product of ligation at 11539.6 Da (calc’d 11540) with less than 10% of CCy5 oligonucleotide at 7329.8
Da (calc’d 7329.1). Low levels of ligation were detected in the presence of PEGs and hexamine cobalt,
where hexamine cobalt caused precipitation of the Cy5-labeled oligonucleotide. These data suggest that
headpieces and/or tags having modified phosphate groups (e.g., modified phosphodiester linkages, such
as phosphorothioate linkages) can be used in any of the binding steps described herein to produce
encoded libraries.
In order to further study the iodo-phosphorothioate ligation reaction, the ligation of 5’-I dT-oligo-
3’-FAM (CFL) and 5’-Cy5-oligo-3’-PS (CCy5) was performed in the absence and presence of a splint
under different reaction conditions.
In a first set of conditions, ligation experiments were conducted with incubation for seven to
eight days. These experiments were performed in the same ligation buffer as above with 50 µM of each
oligonucleotide and incubated for a week at room temperature. Figure 12D shows LC-MS analysis of the
ligation of CFL and CCy5 in the absence (top) and presence (bottom) of a splint (positive control), where
ligation reactions were incubated for seven days. Three LC traces were recorded for each reaction at 260
nm (to detect all nucleic acids), at 495 nm (to detect the CFL oligonucleotide and the ligation product),
and at 650 nm (to detect the CCy5 oligonucleotide and the ligation product).
In the absence of the splint, no ligation occurred, and only starting materials CFL (4339 Da) and
CCy5 (7329 Da) were detected (Figure 12D, top). When the splint oligonucleotide was present for seven
days, a characteristic peak was observed in 495 nm channel with a retention time of 2.98 min, which
corresponds to the ligated product (11542 Da) (Figure 12D, bottom). This peak overlapped with that for
the CCy5 oligonucleotide observed at the 650 nm channel and, thus, was indistinguishable from CCy5 at
650 nm.
Figure 12E shows the LC-MS analysis of CFL and CCy5 in the absence of a splint, where
ligation reactions were incubated for eight days at 400 µM of each oligonucleotide. No ligation product
was detected. Peak 1 (at 495 nm) contained CFL starting material (4339 Da), as well as traces of the loss
of iodine product (4211 Da) and an unknown degradation product (4271 Da, possibly ethyl mercaptane
displacement). Peak 2 (at 650 nm) contained CCy5 starting material (7329 Da) and oxidized CCy5
oligonucleotide (7317 Da). Peak 3 (at 650 nm) contained dimerized CCy5 (14663 Da).
In a second set of conditions, iodine displacement reactions were conducted in the presence of
piperdine and at a pH higher than 7.0. Figure 12F shows MS analysis for a reaction of CFL
oligonucleotide with piperidine, where this reaction was intended to displace the terminal iodine present
in CFL. One reaction condition included oligonucleotides at 100 µM, piperidine at 40 mM (400
equivalents) in 100 mM borate buffer, pH 9.5, for 20 hrs at room temperature (data shown in left panel of
Figure 12F); and another reaction condition included oligonucleotides at 400 µM, piperidine at 2 M
(4,000 equivalents) in 200 mM borate buffer, pH 9.5, for 2 hrs at 65°C (data shown in right panel of
Figure 12F).
In the reaction condition including 40 mM of piperidine (Figure 12F, left), no piperidine
displacement was observed, and a small amount of hydrolysis product was detected (4229 Da). In
addition, traces of the loss of iodine (4211 Da) and unknown degradation product (4271 Da) were
observed. In the reaction condition including 2 M of piperidine (Figure 12F, right), piperidine
displacement of iodine was observed (4296 Da), and the amount of starting material was substantially
diminished (4339 Da). In addition, peaks corresponding to hydrolysis of iodine (by displacement of OH)
or impurity (4229 Da) and loss of iodine (4214 Da) were also observed. These data show that the
presence of an amine (e.g., as part of chemical library synthesis) will not detrimentally effect the
oligonucleotide portion of the library members and/or interfere with this ligation strategy.
In a third set of conditions, splint ligation reactions were conducted in the presence of piperdine
and at a pH higher than 7.0. Figure 12G shows a splint ligation reaction of CFL and CCy5
oligonucleotides at 50 µM performed in the presence of 400 equivalents of piperidine in 100 mM borate
buffer, pH 9.5, for 20 hrs at room temperature. The characteristic peak detected in the LC trace (at 495
nm) contained predominantly the product of ligation at 11541.3 Da (calc’d 11540 Da). Based on these
results, it can be concluded that that piperidine does not impair enzymatic ligation and that the presence
of other amines (e.g., as part of chemical library synthesis) will likely not interfere with this ligation
strategy.
Taking together, these data indicate that this ligation strategy can be performed under various
reaction conditions that are suitable for a broad range of chemical transformations, including extended
incubation times, elevated pH conditions, and/or presence of one or more amines. Thus, the present
methods can be useful for developing library members with diverse reaction conditions and precluding
the necessity of buffer exchange, such as precipitation or other resource-intensive methods.
Example 7
Minimization of shuffling with modified nucleotides
During single-stranded enzymatic ligation with T4 RNA ligase, low to moderate extent of
terminal nucleotide shuffling can occur. Shuffling can result in the inclusion or excision of a nucleotide,
where the final product or complex includes or excludes a nucleotide compared to the expected ligated
sequence (i.e., a sequence having the complete sequence for both the acceptor and donor
oligonucleotides).
Though low levels of shuffling can be tolerated, shuffling can be minimized by including a
modified phosphate group. In particular, the modified phosphate group is a phosphorothioate linkage
between the terminal nucleotide at the 3’-terminus of an acceptor oligonucleotide and the nucleotide
adjacent to the terminal nucleotide. By using such a phosphorothioate linkage, shuffling was greatly
reduced. Only residual shuffling was detected by mass spectrometry, where shuffling likely arose due to
incomplete conversion of the native phosphodiester linkage into the phosphorothioate linkage or to low
levels of oxidation of the phosphorothioate linkage followed by conversion into the native phosphodiester
linkage. Taking together this data and the ligation data in Example 6, one or more modified phosphate
groups (e.g., a phosphorothioate or a 5’-N-phosphoramidite linkage) could be included in any
oligonucleotide sequence described herein (e.g., between the terminal nucleotide at the 3’-terminus of a
headpiece, a complex, a building block tag, or any tag described herein, and the nucleotide adjacent to the
terminal nucleotide) to minimize shuffling during single-stranded ligation.
A single stranded headpiece (ssHP, 3636 Da) was phosphorylated at the 5’-terminus and
modified with a hexylamine linker at the 3’-terminus to provide the sequence of 5’-P-
mCGAGTCACGTC/Aminohex/-3’ (SEQ ID NO: 29). The headpiece was ligated to a tag (tag 15,
XTAGSS000015, 2469 Da) having the sequence of 5’-mCAGTGTCmA-3’ (SEQ ID NO: 30), where mC
and mA indicate 2’-O methyl nucleotides. LC-MS analysis (Figure 13A) revealed that the ligation
product peak contained up to three species, which was partially separated by LC and had the following
molecular weights: 6089 Da (expected), 5769 Da (-320 Da from expected) and 6409 Da (+320 Da from
expected). This mass difference of 320 Da corresponds exactly to either removal or addition of an extra
O-Me C nucleotide (“terminal nucleotide shuffling”).
Experiments with other terminal O-Me nucleotides, as well as terminal 2’-fluoro nucleotides,
confirmed that shuffling likely occurs by cleavage of the 5’-terminal nucleotide of the donor
oligonucleotide, probably after adenylation of the latter. The mechanism of this event is unknown.
Without being limited by mechanism, Figure 13B illustrates a possible scheme for nucleotide reshuffling
during T4 RNA ligase reaction between a headpiece and a tag, where one of skill in the art would
understand that this reaction could occur between any donor and acceptor oligonucleotides (e.g., between
two tags, where one tag is the donor oligonucleotide and the other tag is the acceptor oligonucleotide).
Generally, the majority of the ligation reaction with T4 RNA ligase (T4Rnl1) provides the
expected (normal) ligation product having the combined sequence of both the donor and acceptor
oligonucleotides (Figure 13B-1, reaction on left). A small minority of the reaction provides aberrant
ligation products (Figure 13B-1, reaction on right), where these aberrant products include those having
the removal or addition of a terminal nucleotide (“Product -1 nt” and “Product + 1 nt,” respectively, in
Figure 13B-2).
Without being limited by mechanism, cleavage of the donor oligonucleotide (“headpiece” or
“HP” in Figure 13B-1) may occur by reacting with the 3’-OH group of the acceptor (“tag”), thereby
providing a 5’-phosphorylated donor lacking one nucleotide (“HP-1 nt”) and an adenylated nucleotide
with an accessible 3’-OH group (“1 nt”). Figure 13B-2 shows two exemplary schemes for the reaction
between the headpiece (HP), tag, HP-1 nt, and 1 nt. To provide a product with an excised terminal
nucleotide (Figure 13B-2, left), the 5’-phosphorylated donor lacking one nucleotide (HP-1 nt) acts a
substrate for the ligation event. This HP-1 nt headpiece is re-adenylated by T4 RNA ligase (to provide
“Adenylated HP-1 nt” in Figure 13B-2) and ligated to the tag, resulting in a ligation product minus one
nucleotide (“Product-1 nt”). To provide a product with an additional terminal nucleotide (Figure 13B-2,
left), the adenylated nucleotide (1 nt) likely serves as a substrate for ligation to the tag, thereby producing
an oligonucleotide having one nucleotide longer than the acceptor (“Tag+1 nt”). This Tag+1 nt
oligonucleotide likely serves as an acceptor for the unaltered headpiece, where this reaction provides a
ligation product having an additional nucleotide (“Product+1 nt”). LC-MS analyses of “Product”,
“Product-1 nt”, and “Product+1 nt” were performed (Figure 13B-3). When an aberrant tag and an
aberrant headpiece (i.e., Tag+1 nt and HP-1 nt, respectively) recombine, then the resultant ligation
product is indistinguishable from the expected product.
To further study the mechanism of terminal nucleotide reshuffling, a headpiece (HP-PS) having
the sequence of 5’P-mC*GAGTCACGTC/Aminohex/-3’ (SEQ ID NO: 31) was prepared. Headpiece
HP-PS has the same sequence as ssHP but contains one modification, namely the first phosphodiester
linkage between 5’-terminal nucleotide mC and the following G was synthesized as a phosphorothioate
linkage (one non-bridging phosphate oxygen was substituted by a sulfur). LC-MS analysis of the HP-PS
ligation to tag 15 revealed that shuffling was almost completely inhibited (Figure 13C). Traces of +/- 320
peaks likely correspond to the oxidative conversion of the phosphorothioate linkage into native
phosphodiester linkages or incomplete sulfurization.
Example 8
Size exclusion chromatography of library members
Libraries of chemical entities that are generated using short, single-stranded oligonucleotides as
encoding elements are well suited for the enrichment of binders via size exclusion chromatography
(SEC). SEC is chromatographic technique that separates molecules on the basis of size, where larger
molecules having higher molecular weight flow through the column faster than smaller molecules having
lower molecular weight.
Complexes of proteins and ssDNA library members can be readily separated from unbound
library members using SEC. Figure 14 is an ultraviolet trace from an SEC experiment in which a small
molecule covalently attached to short ssDNA (a range of oligonucleotides with defined lengths in the 20-
50 mer range) was mixed with a protein target known to bind the small molecule. The peaks that elute
first from the column, in the 11-13 minute time range, represent target-associated library members. The
later peaks, eluting from 14-17 minutes, represent unbound library members. The ratio of protein target
to library molecule was 2:1, so approximately 50% of the library molecules should associate with the
protein in the early eluting fraction, as observed in Figure 14. Libraries with larger, double-stranded
oligonucleotide coding regions cannot be selected using this method since the unbound library members
co-migrate with the bound library members on SEC. Thus, small molecule libraries attached to encoding
single-stranded oligonucleotides in the 20-50mer length range enable the use of a powerful separation
technique that has the potential to significantly increase the signal-to-noise ratio required for the effective
selection of small molecule binders to one or more targets, e.g., novel protein targets that are optionally
untagged and/or wild-type protein. In particular, these approaches allow for identifying target-binding
chemical entities in encoded combinatorially-generated libraries without the need for tagging or
immobilizing the target (e.g., a protein target).
Example 9
Encoding with chemically ligated DNA tags using the same chemistry for each ligation step
Encoding DNA tags can be ligated enzymatically or chemically. A general approach to chemical
DNA tag ligation is illustrated in Figure 15A. Each tag bears co-complementary reactive groups on its 5’
and 3’ ends. In order to prevent polymerization or cyclization of the tags, either (i) protection of one or
both reactive groups (Figure 15A), e.g., in case of TIPS-protected 3’ alkynes, or (ii) splint-dependent
ligation chemistry (Figure 15B), e.g., in the case of 5’-iodo/3’-phosphorothioate ligation, is used. For (i),
unligated tags can be removed or capped after each library cycle to prevent mistagging or polymerization
of the deprotected tag. This step may be optional for (ii), but may still be included. Primer extension
reactions, using polymerase enzymes that are capable of reading through chemically ligated junctions,
can also be performed to demonstrate that ligated tags are readable and therefore the encoded information
is recoverable by post-selection amplification and sequencing (Figure 15C).
A library tagging strategy that implements ligation of the tags using “click-chemistry” (Cu(I)
catalyzed azide/alkyne cycloaddition) is shown in Figure 16A. The implementation of this strategy relies
on the ability of precise successive ligation of the tags, avoiding mistagging, and tag polymerizations, as
well as the ability to copy the chemically ligated DNA into amplifiable natural DNA (cDNA) for post-
selection amplification and sequencing (Figure 16C).
To achieve accurate tag ligation triisopropylsilyl (TIPS)-protected 3’ propargyl nucleotides,
(synthesized from propargyl U in the form of a CPG matrix used for oligonucleotide synthesis) was used
(Figure 16B). The TIPS protecting group can be specifically removed by treatment with
tetrabutylammonium fluoride (TBAF) in DMF at 60°C for 1-4 hours. As a result, the ligation during
library synthesis includes a 5’-azido/3’-TIPS-propargyl nucleotide (Tag A) reacting with the 3’-propargyl
of the headpiece through a click reaction. After purification, the previous cycle is treated with TBAF to
remove TIPS and generate the reactive alkyne which in turn reacts with the next cycle tag. The procedure
is repeated for as many cycles as it is necessary to produce 2, 3 or 4 or more successively installed
encoding tags (Figure 16A).
Materials and methods
Oligos: The following oligos were synthesized by Trilink Biotechnologies, San Diego CA: ss-
HP-alkyne: 5’- NH -TCG AAT GAC TCC GAT AT (3’-Propargyl G)-3’(SEQ ID NO: 32); ss-azido-TP:
’-azido dT ATA GCG CGA TAT ACA CAC TGG CGA GCT TGC GTA CTG -3’(SEQ ID NO: 33);
and B-azido: 5’ azido dT ACA CAC TGG CGA GCT TGC GTA CTG -3’ (SEQ ID NO: 34).
ClickTag-TIPS: 5’-azdido dT AT GCG TAC AGT CC (propargyl U-TIPS)-3’ (SEQ ID NO:
) and 5’Dimethoxytrityl 2’-succinyl 3’-O-(triisopropyl silyl) Propargyl uridine cpg were synthesized by
Prime Organics, Woburn MA.
The following oligos were synthesized by IDT DNA technologies, Coralville, IA: FAM-click-
primer: (5’FAM) CAG TAC GCA AGC TCG CC -3’ (SEQ ID NO: 36) and Cy5-click-primer: (5’-
Cy5) CAG TAC GCA AGC TCG CC -3’ (SEQ ID NO: 37).
DNA55-control: /5’Biotin-TEG//ispC3//ispC3/-TCGAATGACTCCGATATGT ATA GCG CGA
TAT ACA CAC TGG CGA GCT TGC GTA CTG -3’ (SEQ ID NO: 38).
rDNA55-control: /5Bio-TEG//ispC3//ispC3/-TCGAATGACTCCGATAT(riboG)T ATA GCG
CGA TAT ACA CAC TGG CGA GCT TGC GTA CTG -3’ (SEQ ID NO: 39)
Synthesis of the templates: In the following examples, the phrase “chemically ligated tags”, or
control sequences related to them, are referred to as “templates” because the subsequent step (“reading”)
utilizes them as templates for template-dependent polymerization.
Tag ligation: To a solution of 1 equivalent (1 mM) of ssHP-alkyne and 1 equivalent (1 mM) of
ss-azidoTP in 500 mM pH 7.0 phosphate buffer, was added a solution of pre-mixed 2 eq of Cu(II)Acetate
(to a final concentration of 2 mM), 4 eq of sodium ascorbate (to a final concentration of 4 mM), 1 eq
TBTA (to a final concentration of 1 mM) in DMF/water. The mixture was incubated at room temperature
overnight. After LC-MS confirmation of the completion of the reaction, the reaction was precipitated
using salt/ethanol.
“Single click” templates Y55 and Y185 were synthesized by the reaction of ss-HP-alkyne with
ss-azido-TP and B-azido, respectively. Double and triple click templates (YDC and YTC) were
synthesized by click ligation of ss-HP-alkyne with ClickTag-TIPS, followed by deprotection of TIPS
using TBAF (tetrabutylammonium fluoride) in DMF at 60°C for an hour, followed by click ligation with
ss-azido TP. For triple click template (YTC), the ligation and deprotection of ClickTag-TIPS was
repeated twice.
The templates were reacted with biotin-(EG)4-NHS and desalted (Figure 17A). The final products
were purified by RP HPLC and/or on a 15-20% polyacryl amide gel/ 8M urea and analyzed by LC-MS.
Enzymes: The following DNA polymerases with their reaction buffers were purchased from New
England Biolabs: Klenow fragment of E. coli DNA polymerase I, Klenow fragment (exo-), E. coli DNA
polymerase I, Therminator™, 9°N™, Superscript III™ .
Streptavidin magnetic Dynabeads® M280 were purchased from Invitrogen.
Template-dependent polymerization assessment: Each template (5 μM) was incubated with 1
equivalent of either Cy5 or FAM Click-primer in 40 to 50 μL of the corresponding 1x reaction buffer and
each enzyme, using reaction conditions according to the manufacturer’s guidelines for 1 hour. Certain
reactions (such as SSII or SSIII transcriptions) were additionally supplemented with 1 mM MnCl . The
product of the reaction was loaded on 125 μL of pre-washed SA beads for 30 minutes with shaking. The
beads were then collected, and the flowthrough was discarded. Beads were washed with 1 mL of Tris-
buffered saline (pH 7.0) and eluted with 35 μL of 100 mM NaOH. The eluate was immediately
neutralized by adding 10 μL of 1 M Tris HCl, pH 7.0. The products were analyzed using LC-MS.
Results and discussion
Template Preparation: Each template, Y55, Y185 (Figures 17B and 17C), YDC and YTC
(Figure 19) was synthesized and purified to greater than 85% purity (the major impurity being un-
biotinylated template). LC-MS revealed the following MWs for the templates: Y55 17,624 (calculated
17,619) Da; YDC 22,228 (calculated 22,228) Da; and YTC 26,832 (calculated 26,837) Da.
The single click templates Y55 and Y185 (Figures 17B and 17C) were synthesized from
oligonucleotides that bear only one click chemistry functionality (alkyne or azide). The efficiency of the
click reaction (chemical ligation) was over 90% in an overnight reaction using Cu(I) catalyst generated in
situ.
Templates YDC and YTC (Figures 19A-19D) serve to demonstrate successive chemical
ligations. Both YDC and YTC use individual tags which simultaneously contain both azido and TIPS-
protected alkyne functionalities. Template YTC demonstrates three successive cycles of tagging as may
be used to encode three steps of chemical library generation.
All of the above templates were tested for primer extension through and beyond the click-ligation
linkages to demonstrate that ligated tags are readable, and therefore that encoded information is
recoverable.
Template-dependent polymerization using “single-click” template Y55: A large set of
polymerases was tested to read through a triazole click linkage (Figure 18A). Initial experiments were
performed using Cy5-click-primer. In later experiments FAM-click-primer was used. The fluorophore
had no effect on the copying of the template, i.e., the results were equivalent using either primer. As a
control template DNA55-control and rDNA55-control were used (to test the effect of a single
ribonucleotide in the template, since propargyl-G used for a click ligation is a ribonucleotide derivative).
Expected full length products in all three templates have the same molecular weight, which is
17446 (FAM primer) (Figure 18B) or 17443 (Cy5 primer). A small amount of the product which
corresponds to primer extension up to, but stopping at, the click ligation linkage (11880 Da) was also
observed for some polymerases.
A set of polymerases that can produce substantial degree of read-through of the click linkage
(production of full-length cDNA) were discovered and are tabulated below.
Full-length cDNA yields of over 50%
Klenow fragment of E. coli DNA polymerase I
Klenow fragment (exo-)
E. coli DNA polymerase I
Therminator™
9°N™
Superscript III™ supplemented with 1 mM MnCl
The highest yields (over 80% read-through at a single click junction) were achieved when using
Klenow fragment with incubation at 37°C (Figure 18B). Somewhat lower yield was observed using E.
coli DNA polymerase I. 50% yields with Therminator™ and 9°N™ polymerases, as well as Klenow
fragment exo- were achieved.
Superscript III™ reverse transcriptase produced about 50% yield of cDNA when the buffer was
supplemented with 1 mM MnCl . However, manganese caused the mis-incorporation of nucleotides
which was observed by MS, i.e., polymerization fidelity was reduced.
Template-dependent polymerization using “single-click” template Y185: Template Y185 features
the same primer binding site as all templates used in this example, except, due to a different tailpiece B-
azido, the distance between the last nucleotide of the primer binding site to the click linkage is 8
nucleotides, as compared to 20 nucleotides in Y55 and all other templates. The template was used to test
whether transcription of a click linkage was still possible when the enzyme was in initiation-early
elongation conformation. Klenow was capable of copying the Y185 template with similar efficiency to
Y55, opening the possibility of reducing the length of the click-ligated encoding tags (Figure 18C).
Template-dependent polymerization using double and triple click-ligated templates YDC and
YTC: After establishing that the Klenow fragment was the most efficient enzyme to read through the click
ligation linkages under the assay condition employed, cDNA using YDC and YTC templates (Figures
20A-20C) were also generated. Primer extension reactions with both YDC and YTC templates produced
full length products. Other observed products, which composed around 10-15% of total reaction output,
corresponded to partially extended primer, stalled at each click junction, such as e.g., 11880 Da and
16236 Da. The yields were measured by LC-MS analysis in the presence of the internal standard and
were about 80-90% per junction (i.e., around 85% for 1 click, 55% for 2-click and 50% for 3-click
templates, see Figure 21).
The product of YDC transcription lacked 1 dA nucleotide (calculated 22110, observed 27197 Da;
-313 dA Figure 20B) and the product of YTC transcription lacked 2 dA nucleotides (calculated 26773,
observed 26147; -626 2xdA) (Figure 20C). This correlates with the number of propargyl U nucleotides in
the template. Without wishing to be limited by mechanism, it can be hypothesized that Klenow skipped
over those U’s in the context of T-triazole-U junction. In contrast, the propargyl G nucleotide in the 1
click junction was correctly copied.
Example 10
Use of 3’-phosphorothioate/5’-iodo tags to chemically ligate a succession of encoding DNA tags that
encode a chemical library covalently installed upon the 5’-terminus
Protection of 3’-phosphorothioate on tag: As shown in Figure 24A, a 5’-iodo-3’-
phosphorothioate tag (1 eq.) was dissolved in water to give a final concentration of 5 mM. Subsequently,
vinyl methyl sulfone (20 eq.) was added and the reaction was incubated at room temperature overnight.
Upon completion of the reaction, the product was precipitated by ethanol.
Library synthesis (Figure 24B)
Cycle A: To each well in the split was added single-stranded DNA headpiece (1 eq., 1 mM
solution in 500 mM pH 9.5 borate buffer), one cycle A protected tag (1.5 eq.), and splint (1.2 eq.). The
chemical ligation was incubated at room temperature overnight. To each well (in the split) was then
added one Fmoc amino acid (100 eq.), followed by 4-(4,6-dimethoxy-1,3,5-triazinyl)
methylmorpholinium chloride (100 eq.). The chemical reaction was incubated at room temperature
overnight. Upon completion, all wells were pooled and the products precipitated using ethanol. The
cycle A pool was purified using LC and lyophilized to dryness, and then dissolved in water to give a 1
mM final concentration and piperidine (10% v/v) was added to perform the deprotection of cycle A tag
(60°C, 2h). The deprotected product was precipitated again using ethanol.
Cycle B: The deprotected cycle A pool was dissolved in 500 mM, pH 9.5, borate buffer to give a
1mM concentration and then split into separate reaction wells (1 eq. of cycle A product in each well). To
each well was added one cycle B protected tag (1.5 eq.), and splint (1.2 eq.). The chemical ligation was
incubated at room temperature overnight. To each well (in the split) was added a mixture of one formyl
acid (100 eq.), diisopropyl carbodiimide (100 eq.) and 1-hydroxyaza-benzotriazole (100 eq.). The
chemical reaction was incubated at room temperature overnight. Upon completion, all wells were pooled
and the products precipitated using ethanol. The cycle B pool was purified using LC and lyophilized to
dryness, and then dissolved in water to give a 1 mM final concentration and piperidine (10% v/v) was
added to perform the deprotection of cycle B tag (60°C, 2h). The deprotected product was precipitated
again using ethanol.
Cycle C: The deprotected cycle B pool was dissolved in 500 mM pH 5.5 phosphate buffer to
give a 1 mM concentration and then split into separate reaction wells (1 eq. of cycle B product in each
well). To each well was added one cycle C tag (1.5 eq.) and splint (1.2 eq.). The chemical ligation was
incubated at room temperature overnight. To each well (in the split) was added an amine (80 eq.) and
sodium cyanoborohydride (80 eq.). The chemical reaction was incubated at 60°C for 16h. Upon
completion, all wells were pooled and the products precipitated using ethanol. The cycle C pool was
purified using LC and lyophilized to dryness.
Example 11
Encoding with chemically ligated DNA tags using a pair of orthogonal chemistries for each
successive tag ligation step
Another approach for generation of chemically ligated encoding DNA tags is the use of a pair of
orthogonal chemistries for successive ligations (Figure 22A). Tags that bear orthogonal reactive groups
at their ends will not tag polymerize or cyclize, and the orthogonal nature of successive ligation steps will
reduce the frequency of mistagging events. Such approaches require (i) having at least two orthogonal
chemistries available for oligonucleotide conjugation, and (ii) available read-through strategy for each of
the junctions thus created (Figures 22B and 22C). This approach may also obviate the need for the use of
protection groups or capping steps, thereby simplifying the tag ligation process.
Orthogonal chemical ligation strategy utilizing 5’-Azido/3’-Alkynyl and 5’-Iodo/3’-
Phosphorothioate ligation for successive steps: An example of the use of two orthogonal chemistries tag
ligation is the combination of 5’-azido/3’-alkynyl and 5’-iodo/3’-phosphorothioate ligations. Figure 23
shows an exemplary schematic of the synthesis of a 3-cycle orthogonal chemical ligation tagging strategy
using these successive ligation chemistries. Figures 25A-25B show an example of the use of 3’-
phosphorothioate/5’-azido and 3’-propargyl/5’-iodo tags to chemically ligate a succession of orthogonal
encoding DNA tags that encode a chemical library covalently installed upon the 5’-terminus.
Protection of 3’-phosphorothioate on tags: As shown in Figure 25A, a 5’-azido-3’-
phosphorothioate tag (1 eq.) was dissolved in water to give a final concentration of 5 mM. Subsequently,
vinyl methyl sulfone (20 eq.) was added and the reaction was incubated at room temperature overnight.
Upon completion of the reaction, the product was precipitated by ethanol.
Library synthesis (Figure 25B)
Cycle A: To each well in the split was added single stranded DNA headpiece (1 eq., 1 mM
solution in 500 mM pH 9.5 borate buffer), one cycle A tag (1.5 eq.), and splint (1.2 eq.). The chemical
ligation was incubated at room temperature overnight. To each well (in the split) was then added one
Fmoc amino acid (100 eq.), followed by 4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium
chloride (100 eq.). The chemical reaction was incubated at room temperature overnight. Upon
completion, all wells were pooled and the products precipitated using ethanol. The cycle A pool was
purified using LC and lyophilized to dryness. Fmoc deprotection was performed on cycle A pool by
treating the pool (1mM in water) with piperidine (10% v/v) for 2h at room temperature. The deprotected
product was precipitated again using ethanol.
Cycle B: The purified cycle A pool was dissolved in 500 mM, pH 7.0 phosphate buffer to give a
1 mM concentration and then split into separate reaction wells (1 eq. of cycle A product in each well). To
each well was added one cycle B protected tag (1.2 eq.), copper (II) acetate (2 eq.), sodium ascorbate (4
eq.), and tris-(benzyltriazolylmethyl)amine (1 eq.). The chemical ligation was incubated at room
temperature overnight. Upon completion, the products were precipitated (in the split) using ethanol and
then diluted to a 1 mM concentration using 500 mM, pH 9.5 borate buffer. To each well (in the split) was
then added a mixture of one formyl acid (100 eq.), diisopropyl carbodiimide (100 eq.), and 1-hydroxy
aza-benzotriazole (100 eq.). The chemical reaction was incubated at room temperature overnight. Upon
completion, all wells were pooled and the products precipitated using ethanol. The cycle B pool was then
dissolved in water to give a 1 mM final concentration, and piperidine (10% v/v) was added to perform the
deprotection of cycle B tag (room temperature, 18h). The deprotected product was precipitated again
using ethanol. The deprotected Cycle B pool was purified using LC and lyophilized to dryness.
Cycle C: The purified cycle B pool was dissolved in 500 mM, pH 5.5 phosphate buffer to give a
1 mM concentration and then split into separate reaction wells (1 eq. of cycle B product in each well). To
each well was added one cycle C tag (1.5 eq.) and splint (1.2 eq.). The chemical ligation was incubated at
room temperature overnight. To each well (in the split) was added an amine (80 eq.) and sodium
cyanoborohydride (80 eq.). The chemical reaction was incubated at 60°C for 16h. Upon completion, all
wells were pooled and the products precipitated using ethanol. The cycle C pool was purified using LC
and lyophilized to dryness.
Other embodiments
All publications, patent applications, and patents mentioned in this specification are herein
incorporated by reference.
Various modifications and variations of the described method and system of the invention will be
apparent to those skilled in the art without departing from the scope and spirit of the invention. Although
the invention has been described in connection with specific desired embodiments, it should be
understood that the invention as claimed should not be unduly limited to such specific embodiments.
Indeed, various modifications of the described modes for carrying out the invention that are obvious to
those skilled in the fields of medicine, pharmacology, or related fields are intended to be within the scope
of the invention.
In this specification where reference has been made to patent specifications, other external
documents, or other sources of information, this is generally for the purpose of providing a context for
discussing the features of the invention. Unless specifically stated otherwise, reference to such external
documents is not to be construed as an admission that such documents, or such sources of information, in
any jurisdiction, are prior art, or form part of the common general knowledge in the art.
The term “comprising” as used in this specification and claims means “consisting at least in part
of”. When interpreting statements in this specification, and claims which include the term “comprising”,
it is to be understood that other features that are additional to the features prefaced by this term in each
statement or claim may also be present. Related terms such as “comprise” and “comprised” are to be
interpreted in similar manner.
Claims (17)
1. A method of tagging a first library comprising an oligonucleotide-encoded small molecule or peptide, said method comprising: (i) providing a headpiece having a first functional group and a second functional group, wherein said headpiece comprises at least one 2’-substituted nucleotide, wherein said headpiece comprises a 2’-substituted nucleotide at the 5’-terminus and/or 3’-terminus; (ii) binding said first functional group of said headpiece to a first component of said small molecule or peptide, wherein said headpiece is directly connected to said first component or said headpiece is indirectly connected to said first component by a bifunctional linker; and (iii) binding said second functional group of said headpiece to a first building block tag to form a complex, wherein said steps (ii) and (iii) can be performed in any order and wherein said first building block tag encodes for the binding reaction of said step (ii), thereby providing a tagged library.
2. The method of claim 1, wherein said first building block tag comprises at least one 2’- substituted nucleotide, such as a 2’-O-methyl nucleotide or a 2’-fluoro nucleotide.
3. The method of claim 1 or 2, wherein said 2’-substitued nucleotide is 2’-O-methyl guanine, 2’-O-methyl uracil, 2’-O-methyl adenosine, 2’-O-methyl thymidine, 2’-O-methyl inosine, 2’-O-methyl cytidine, 2’-O-methyl diamino purine, 2’-fluoro guanine, 2’-fluoro uracil, 2’-fluoro adenosine, 2’-fluoro thymidine, 2’-fluoro inosine, 2’-fluoro cytidine, or 2’-fluoro diamino purine.
4. The method of any one of claims 1-3, wherein step (ii) comprises binding said headpiece directly to said first component.
5. The method of any one of claims 1-3, wherein step (ii) comprises binding said headpiece indirectly to said first component via a bifunctional linker.
6. The method of any one of claims 1-5, further comprising (iv) binding a second building block tag to the 5’-terminus or 3’-terminus of said complex; and (v) binding a second component of said chemical library to said first component, wherein said steps (iv) and (v) can be performed in any order.
7. The method of claim 6, wherein said second building block tag comprises a 2’- substituted nucleotide at one or more of the 5’-terminus, the 3’-terminus, or the internal position of said second building block tag.
8. The method of any one of claims 1-7, wherein said step (iii) or step (iv), if present, comprises an RNA ligase and/or a DNA ligase to bind said second building block tag to said complex and/or comprises poly ethylene glycol and/or one or more soluble multivalent cations.
9. The method of any one of claims 1-8, wherein said method further comprises separating said complex from any unreacted tag or unreacted headpiece before any one of binding steps (ii)-(iii) and/or, if present, steps (iv)-(v), and/or purifying said complex before any one of binding steps (ii)-(iii) and/or, if present, steps (iv)-(v).
10. The method of any one of claims 1-9, wherein said method further comprises binding one or more additional building block tags to said complex and binding one or more additional components to said complex.
11. The method of any one of claims 1-10, wherein said headpiece comprises a hairpin structure.
12. The method of any one of claims 1-11, wherein said headpiece, said first building block tag, said second building block tag, and/or said one or more additional building block tags, if present, further comprises a first library-identifying sequence, a use sequence, and/or an origin sequence.
13. The method of any one of claims 1-12, wherein said method further comprises binding a first library-identifying tag, a use sequence, an origin sequence, and/or a tailpiece to said complex.
14. The method of any one of claims 1-13, wherein said method comprises a plurality of headpieces.
15. A complex comprising a headpiece and a building block tag, wherein said tag comprises from 5 to 20 nucleotides, a 2’-substituted nucleotide at the 5’-terminus, and a 2’- substituted nucleotide at the 3’-terminus, wherein said headpiece is directly connected to a small molecule or peptide or said headpiece is indirectly connected to a small molecule or peptide by a bifunctional linker.
16. A method as defined in claim 1 substantially as herein described with reference to any example thereof.
17. A complex as claimed in claim 15 substantially as herein described with reference to any example thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ722289A NZ722289B2 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161531820P | 2011-09-07 | 2011-09-07 | |
US61/531,820 | 2011-09-07 | ||
US201161536929P | 2011-09-20 | 2011-09-20 | |
US61/536,929 | 2011-09-20 | ||
PCT/US2012/054228 WO2013036810A1 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ621592A NZ621592A (en) | 2016-08-26 |
NZ621592B2 true NZ621592B2 (en) | 2016-11-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210002630A1 (en) | Methods for tagging dna-encoded libraries | |
AU2020239663A1 (en) | DNA-encoded libraries having encoding oligonucleotide linkages not readable by polymerases | |
NZ621592B2 (en) | Methods for tagging dna-encoded libraries | |
NZ722289B2 (en) | Methods for tagging dna-encoded libraries |